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ABSTRACT OF DISSERTATION

EPIGENETIC STATES REGULATE TUMOR AGGRESSIVENESS AND
RESPONSE TO TARGETED THERAPIES IN LUNG ADENOCARCINOMA

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related
death worldwide, 85% of which are lung adenocarcinomas (LUAD). Although
molecular studies of NSCLC identified targetable mutations of some oncogenes
including BRAF, EGFR and ALK, no targeted therapies exist for most cases.
Cancer epigenetics is the study of epigenetic modifications, including histone
modifications, that control gene expression in cancer. Recent advances have
revealed numerous epigenetic abnormalities in human cancers, and targeting
epigenetic regulators could be effective at reversing dysregulated epigenetic
programs or driving sensitivity to other targeted therapies.
Inhibitors of the histone methyltransferase EZH2 have recently been
approved as single agents for specific solid tumors including lymphoma and
sarcoma. In the first project, by using a genetic model to delete Ezh2 in KRASdriven LUAD, we observed that Ezh2 haplo-insufficient tumors were less lethal and
lower grade than Ezh2 full-insufficient tumors, which were poorly differentiated and
metastatic. By using three-dimensional (3D) cultures and in vivo experiments, we
identified that EZH2 deficient tumors were vulnerable to H3K27 demethylase and
BET inhibitors. EZH2 and BET inhibitors also strongly synergized in human lung
cancer cells. Mechanistically, EZH2 depletion led to de-repression of the
embryonic transcription factor FOXP2, promoting stemness and migration. In
human lung cancers, poorly differentiated tumors were enriched for an H3K27me3low state. Together these data uncover the role of EZH2 activity in the
aggressiveness of LUAD and suggest that EZH2 inhibitors will be most effective
as low dose single therapies or in combination with drugs including BET inhibitors
for LUAD. In the second project, we observed that the PIK3CA-mutant or amplified
lung cancer cells were more sensitive to EZH2 inhibition. EZH2 inhibitor had
combinatorial synergy with PI3K inhibitor in PIK3CA-mutant or amplified lung

cancers both in vitro and in vivo. This study suggested a promising combination
therapy in combating the LUAD with PIK3CA mutation or amplification.
Targeting the epidermal growth factor receptor (EGFR) with tyrosine kinase
inhibitors (TKIs) is one of the major precision medicine options for LUAD. While
first- and second-generation TKIs were plagued by development of drug resistance,
third-generation inhibitors including osimertinib and rociletinib were developed. In
the third project, we describe a model of EGFR driven lung cancer and a method
to develop tumors of distinct epigenetic states through 3D organotypic cultures.
We discovered that activation of EGFR T790M/L858R mutation in lung epithelial
cells can drive lung cancers with alveolar or bronchiolar features, which can be
originated from alveolar type 2 (AT2) cells or bronchioalveolar stem cells (BASCs),
but not basal cells or club cells. We also demonstrated that these clones were able
to retain their epigenetic differences through passaging orthotopically in mice, and
crucially that they had distinct drug vulnerabilities. This work serves as a blueprint
for exploring how epigenetics can be used to stratify patients for precision medicine
decisions.
KEY WORDS
KEYWORDS: Cancer Epigenetics, EZH2, EGFR, PIK3CA, Targeted Therapy

Fan Chen
(Name of Student)
04/06/2021
Date

EPIGENETIC STATES REGULATE TUMOR AGGRESSIVENESS AND
RESPONSE TO TARGETED THERAPIES IN LUNG ADENOCARCINOMA

By
Fan Chen

Dr. Christine Fillmore Brainson
Co-Director of Dissertation
Dr. Jill Kolesar
Co-Director of Dissertation
Dr. Isabel Mellon
Director of Graduate Studies
04/19/2021
Date

DEDICATION
I would like to dedicate this work to my parents and grandmother, who have
always been supportive to me on every step of my progression.

ACKNOWLEDGMENTS
I really want to express my sincere gratitude to my mentors, colleagues,
families, and friends. Without your help and support, I would not be able to
successfully complete my graduate study.
First of all, I want to thank my thesis advisor, Dr. Christine Fillmore
Brainson, for her wonderful mentorship not only in research and academic
knowledge, but also in teaching me how to keep a kind attitude and the spirit of
cooperation to other colleagues and how to balance life and work. Also, I want to
thank all my lab members and collaborators, especially Xiulong Song, for all the
kind help you gave to me. Furthermore, I would like to thank Dr. Jill Kolesar, Dr.
Chengfeng Yang and Dr. Chi Wang to be my thesis committee members and
supervise me successfully accomplishing the PhD program. Moreover, I want to
thank director of graduate study Dr. Isabel Mellon and Dean of our department
Dr. Xiaoqi Liu for your firm support. I should also thank my previous mentors in
medical school, Dr. Benkang Shi and Dr. Gang Yin, for all the sources you
provided to help me get admitted into the PhD programs. Graduate school is
stressful, and my friends here in the United States and back in China helped me
get out of the stress and anxiety. Lastly, I want to thank the PhD program. PhD
program is a long journey full of difficulties, frustrations, happiness, and also
progressions. Approaching the end of this journey, I not only learn how to do
research, which is my initial purpose, but also unexpectedly gain a better
understanding of the world and life, and know better how to enjoy my future life.

iii

TABLE OF CONTENTS
ACKNOWLEDGMENTS ................................................................................................................. iii
LIST OF TABLES ......................................................................................................................... viii
LIST OF FIGURES ....................................................................................................................... viii
LIST OF MANUSCRIPTS ............................................................................................................... xi
CHAPTER 1. INTRODUCTION ........................................................................................................ 1

1.1 Epigenetics and cancer epigenetics .......................................................... 1
1.1.1 Chromatin and epigenetics ...................................................................... 1
1.1.2 Epigenetics in cancer ............................................................................... 3
1.2 Polycomb Repressive Complex 2 and cancer ........................................... 6
1.2.1 Functions of PRC2 ................................................................................... 6
1.2.2 PRC2 in cancer and epigenetics .............................................................. 8
1.3 Targeted therapies in non-small cell lung cancer..................................... 11
1.3.1 Non-small cell lung cancer and current therapies .................................. 11
1.3.2 EGFR in lung cancer .............................................................................. 14
1.3.3 PI3K in lung cancer ................................................................................ 15
1.4 Technological advances for 3-dimensional organotypic culture ............... 16
1.5 Goal of the projects .................................................................................. 20
CHAPTER 2. MATERIALS AND METHODS................................................................................. 21

iv

2.1 Cell lines .................................................................................................. 21
2.2 Animals .................................................................................................... 22
2.3 Patient samples ....................................................................................... 24
2.4 Flow cytometry analysis and sorting ........................................................ 25
2.5 7AAD cell cell flow cytometry analysis ..................................................... 25
2.6 MRI of genetically engineered mouse model ........................................... 26
2.7 Tumor cell 3D culture ............................................................................... 27
2.8 Cell viability assay ................................................................................... 29
2.9 Soft agar transformation assay ................................................................ 30
2.10 Crystal violet growth assay ...................................................................... 30
2.11 Quantitative RT PCR and RNA-sequencing ............................................ 31
2.12 Principal component analysis (PCA) ........................................................ 32
2.13 Gene ontology enrichment ....................................................................... 33
2.14 Gene set enrichment analysis.................................................................. 34
2.15 Chromatin Immunoprecipitation and qPCR (ChIP-qPCR)........................ 34
2.16 Western blotting ....................................................................................... 36
2.17 Histology and immunohistochemistry....................................................... 37
2.18 Transwell cell migration assay ................................................................. 39
2.19 Viruses ..................................................................................................... 39

v

2.20 Statistics and reproducibility .................................................................... 41
CHAPTER 3. POLYCOMB DEFICIENCY DRIVES A FOXP2-HIGH AGGRESSIVE STATE
TARGETABLE BY EPIGENETIC INHIBITORS ............................................................................ 43

3.1 Brief introduction ...................................................................................... 43
3.2 Ezh2 haplo- and full-Insufficiency drive distinct phenotypes in
KRAS+/Trp53-null lung cancer ....................................................................... 46
3.3 Model systems differ in cell cycle and gene expression........................... 53
3.4 Ezh2 deficiency leads to diverse gene expression in different models .... 63
3.5 Loss of PRC2 activity drives increased FOXP2 expression in normal and
malignant lung cells ........................................................................................ 72
3.6 FOXP2 dictates stemness and migratory capacity of lung epithelial cells 77
3.7 Polycomb deficiency drives BET and histone de-methylase inhibitor
sensitivity ........................................................................................................ 87
3.8 High EZH2 correlates with low H3K27me3 and high FOXP2 and predicts
advanced lung cancer ..................................................................................... 95
3.9 Summary and discussion ....................................................................... 102
CHAPTER 4. EZH2 INHIBITION CONFERS PIK3CA-DRIVEN LUNG TUMORS ENHANCED
SENSITIVITY TO PI3K INHIBITION............................................................................................ 106

4.1 Brief introduction .................................................................................... 106
4.2 PIK3CA mutated or amplified cell lines have increased sensitivity to EZH2
inhibition ........................................................................................................ 108
vi

4.3 PIK3CA-E545K induces moderate transformation in lung epithelial cells
112
4.4 Pik3ca-E545K with p53 loss drives lung adenocarcinomas in a novel
mouse model ................................................................................................ 117
4.5 EZH2 inhibition synergizes with PI3K inhibition in lung cancer .............. 122
4.6 Summary and discussion ....................................................................... 129
CHAPTER 5. EPIGENETIC STATE DETERMINES SENSITIVITY OF EGFR-DRIVEN LUNG
CANCER CELLS TO THERAPY................................................................................................. 131

5.1 Brief introduction .................................................................................... 131
5.2 The autochthonous LSL:EGFR T790M/L858R model develops lung
adenocarcinoma in mice ............................................................................... 133
5.3 Distal lung stem/progenitor cells efficiently undergo ex vivo malignant
transformation by mutant EGFR ................................................................... 137
5.4 Different stem/progenitor cells drive distinct gene expression during
malignant transformation............................................................................... 144
5.5 Bronchiolar and alveolar tumoroids respond to therapies differentially .. 151
5.6 Summary and discussion ....................................................................... 159
CHAPTER 6. SUMMARY AND FITURE DIRECTIONS ............................................................... 161
REFERENCES............................................................................................................................. 164
VITA ............................................................................................................................................. 187

vii

LIST OF TABLES
Table 3. 1 Gene Enrichment for Principle Component 3 on All Models (Top 40) 61
Table 3. 2 Gene Set Enrichment Analysis Model Compare ................................ 62
Table 3. 3 Gene Set Enrichment Analysis Ezh2 Null vs Ezh2 WT...................... 70
Table 3. 4 Gene Set Enrichment Analysis Ezh2 Het vs Ezh2 WT or Ezh2 Null .. 71
Table 3. 5 Gene Set Enrichment Analysis of FOXP2 oe vs Empty Vector ......... 86

LIST OF FIGURES
viii

LIST OF FIGURES
Figure 3. 1 Ezh2 haplo- and full-Insufficiency drive distinct tumor burdens in
KRAS+/Trp53-null lung cancer ........................................................................... 49
Figure 3. 2 Ezh2 haplo- and full-Insufficiency drive distinct phenotypes in
KRAS+/Trp53-null lung cancer ........................................................................... 51
Figure 3. 3 Model systems differ in morphology and expression of PRC2
molecules ........................................................................................................... 57
Figure 3. 4 Model systems differ in cell cycle ..................................................... 58
Figure 3. 5 Model systems differ in gene expression.......................................... 59
Figure 3. 6 Ezh2 deficiency leads to diverse gene expression in different models
........................................................................................................................... 66
Figure 3. 7 Ezh2 deficiency leads to diverse enriched gene signatures in different
models ................................................................................................................ 68
Figure 3. 8 Loss of PRC2 activity drives increased FOXP2 expression in murine
lung cancer cells ................................................................................................. 74
Figure 3. 9 Loss of PRC2 activity drives increased FOXP2 expression in human
normal and malignant lung cells ......................................................................... 75
Figure 3. 10 Loss of PRC2 activity drives increased H3K27ac and decreased
H3K27me3 at genomic regions of FOXP2 expression ....................................... 76
Figure 3. 11 FOXP2 dictates stemness of lung epithelial cells ........................... 80
Figure 3. 12 FOXP2 dictates migratory capacity of lung epithelial cells ............. 81
Figure 3. 13 FOXP2 overexpression confers resistance to chemotherapy ......... 82
Figure 3. 14 FOXP2 overexpression cooperates with PRC2 to regulate gene
expression .......................................................................................................... 83
Figure 3. 15 FOXP2 knockdown suppresses cell proliferation, organoid formation
and migration of lung cancer .............................................................................. 84
Figure 3. 16 Polycomb deficiency drives BET and histone de-methylase inhibitor
sensitivity in murine 3D culture in vitro ............................................................... 90
Figure 3. 17 Polycomb deficiency drives BET inhibitor sensitivity in murine
tumors in vivo ..................................................................................................... 91
Figure 3. 18 EZH2 inhibition synergizes with BET inhibition in mouse and human
cancers ............................................................................................................... 93
Figure 3. 19 EZH2 correlates with high FOXP2 expression, low H3K27me3 and
poorly differentiated lung tumors ........................................................................ 98
Figure 3. 20 S-Adenosyl methionine regulates PRC2 stability and activity ....... 100
Figure 3. 21 EZH2 and FOXP2 correlates with worse prognosis in lung
adenocarcinoma ............................................................................................... 101
Figure 4. 1 Landscape of PIK3CA mutations in lung cancer patients ............... 109
Figure 4. 2 PIK3CA mutated or amplified cell lines have increased sensitivity to
EZH2 inhibition ................................................................................................. 110
Figure 4. 3 PIK3CA-E545K mutation activates downstream pathways in lung
epithelial cells ................................................................................................... 113
ix

Figure 4. 4 PIK3CA-E545K does not affect colony formation in soft agar in lung
epithelial cells ................................................................................................... 114
Figure 4. 5 PIK3CA-E545K induces moderate transformation in lung epithelial
cells in 3D Matrigel culture ............................................................................... 115
Figure 4. 6 Pik3ca-E545K with p53 loss drives lung cancer in a novel mouse
model ................................................................................................................ 118
Figure 4. 7 Pik3ca-E545K with p53 loss drives autochthonous LADC.............. 119
Figure 4. 8 Pik3ca-E545K/p53-loss tumors form alveolar tumor organoids ...... 120
Figure 4. 9 EZH2 inhibition synergizes with PI3K inhibition in lung cancer cell
lines in vitro....................................................................................................... 123
Figure 4. 10 PIK3CA WT and E545K do not change sensitivity to GSK126 in lung
epithelial cells ................................................................................................... 124
Figure 4. 11 EZH2 inhibition synergizes with PI3K inhibition in lung epithelial cells
with or without PIK3CA mutation in vitro ........................................................... 125
Figure 4. 12 EZH2 inhibition and PI3K inhibition reduce PIK3IP1 expression .. 126
Figure 4. 13 EZH2 inhibition cooperates with PI3K inhibition in lung cancer cells
in vivo ............................................................................................................... 127
Figure 5. 1 The autochthonous LSL:EGFR T790M/L858R model develops lung
cancer in mice .................................................................................................. 135
Figure 5. 2 The autochthonous LSL:EGFR T790M/L858R model develops lung
adenocarcinoma with alveolar or bronchiolar features in mice ......................... 136
Figure 5. 3 Schematic of cell-of-origin study in lung stem or progenitor cells ... 139
Figure 5. 4 BASC-derived EGFR-activated organoids form alveolar and
bronchiolar architectures in 3D culture ............................................................. 140
Figure 5. 5 Distal lung stem/progenitor cells efficiently undergo ex vivo malignant
transformation by mutant EGFR ....................................................................... 141
Figure 5. 6 BASC and AT2 derived organoids develop ex vivo transformed
tumors with distinct lineage features................................................................. 143
Figure 5. 7 Schematic of RNA-sequencing analysis from different stages of
organoids and tumoroids .................................................................................. 147
Figure 5. 8 Different stem/progenitor cells drive distinct gene expression during
malignant transformation .................................................................................. 148
Figure 5. 9 AT2 and BASC derived EGFR-mutant cells are transcriptionally
different ............................................................................................................ 149
Figure 5. 10 Bronchiolar and alveolar tumor tumoroids differ in lineage markers
and morphologies ............................................................................................. 154
Figure 5. 11 Bronchiolar and alveolar tumor tumoroids have distinct IC50 to
therapies ........................................................................................................... 155
Figure 5. 12 Bronchiolar and alveolar tumoroids respond to therapies
differentially ...................................................................................................... 156
Figure 5. 13 Third generation TKI osimertinib synergizes with EZH2 inhibition,
BET inhibition and PI3K inhibition in lung cancer cells ..................................... 157

x

LIST OF MANUSCRIPTS
(The manuscripts listed here are discussed in this dissertation)
Chen F., Byrd A.L., Liu J., Flight R.M., DuCote T.J., Bakhtiari M., Song X., Edgin
A.R., Lukyanchuk A., Dixon D.T., Jayswal R.D., Orkin S.H., Moseley H.N.B.,
Wang C., Brainson C.F. Polycomb deficiency drives a FOXP2-high aggressive
state targetable by epigenetic inhibitors. Under Review at Nature
Communications, in revision.
Chen F., Liu J., Flight R.M., Edgin A.R., Song X., Wong K.K., Zhang H., Moseley
H.N.B., Wang C., Brainson C.F. Epigenetic state determines sensitivity of EGFRdriven lung cancer cells to therapy. In preparation.
Chen F.*, Song X., DuCote T.J., Byrd A.L., Brainson C.F. EZH2 inhibitors
confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition. In
preparation.
Chen F., Lee J.H., Brainson C.F. Using 3-dimensional cultures to propagate
genetically modified lung organoids. Tissue Morphogenesis: Methods and
Protocols Second Edition. Methods in Molecular Biology, In press.

xi

CHAPTER 1. INTRODUCTION
1.1

Epigenetics and cancer epigenetics
1.1.1 Chromatin and epigenetics
Eukaryotic chromatin, located in the nucleus of cells, is a precise compact

structure of macromolecules within a chromosome.1 It contains DNAs, RNAs and
histone proteins. The main role of chromatin is to package the long DNA molecules
into more compressed and denser structures by wrapping the DNAs around the
histone molecules in tight coil so that to make them fit into the nucleus.2 The
chromatin is further coiled into condensed chromosome, which is the higher order
of the DNA organization.3 Chromatin also gets involved in many biological
processes including transcription regulation and DNA repair through the dynamic
regulation of chromatin organization.4,5
The core histone octamer is composed of four pairs of histone proteins
H2A, H2B, H3 and H4. Histone H1 is not the core component of the octamer but
helps stabilize the chromatin fiber between chromosomes.6,7 Histone proteins are
basic and thus positively charged, which enables them to tightly associate with
negatively charged DNA molecules.8 The modifications or variant incorporation of
histone proteins and chromatin remodeling precisely regulate the chromatin
structure and thus greatly influence the gene expression.
Epigenetics is the study of gene expression alterations without changing the
nucleotide sequence.9 Cellular differentiation from embryonic stem cells to
terminally differentiated cells is an example of normal epigenetic regulation.
1

Epigenetic regulation consists of four main categories: DNA methylation, histone
modification, nucleosome remodeling and RNA-mediated targeting.10 Addition of
methyl groups onto DNA strain can result in limited accessibility of transcription
machinery in a specific genomic region, and thereafter inactivate the gene
transcription.11,12 Histone tail methylation and acetylation are the major
posttranscriptional modifications of histone components.13 Others include histone
phosphorylation,

ubiquitylation,

sumoylation,

O-GlnNAc-glucosamine,

ADP

ribosylation, glycosylation, hydroxylation, proline isomerization, formylation,
succinylation and citrullination.8 Transferring an acetyl group to the side chain of
histone tail could neutralize the positive charge of DNA molecule and loosen the
electrostatic interactions between DNAs and histone octamer, which depresses
the gene transcription in that genomic region. On the contrary, methylation of the
histone tail stabilizes the DNA-histone association and suppresses the gene
expression.14 Enzymes that can write, erase, or read these modifications in the
histone side chains play an important role in histone-mediated regulation.
Chromatin remodeling or reorganization is a dynamic alteration of chromatin
architecture, comprising nucleosome reposition, eviction and histone variant
replacement.15,16 One of the most important complexes is SWI/SNF chromatin
remodeling complex, also known as BRG/BRM-associated factor (BAF) complex
in mammals. SWI/SNF complexes can destabilize histone-DNA interaction and
remodel chromatin nucleosomes in an ATP-dependent manner to regulate gene
expression.17-19 Non-coding RNAs and RNA modifications can also mediate
epigenetic regulation. Non-coding RNAs are the RNA molecules which are not

2

eventually translated into protein, and include microRNAs, short interfering RNAs
and long non-coding RNAs.20,21 Non-coding RNAs participate in translation, RNA
splicing, DNA replication and many other biological activities. Moreover, the most
abundant mRNA post-transcriptional chemical modification in mammals is RNA
N6-methyladenosine (m6A).22,23 m6A RNA methylation engages in mRNA splicing,
transportation and stabilization.
The advances of technologies in studying the epigenetics recent years
greatly help the understanding of epigenome, not only in the specific genomic
regions, but also in a larger genome-wide scale. The epigenetic techniques used
frequently include chromatin immunoprecipitation with sequencing (ChIP-seq),
assay for transposase-accessible chromatin with sequencing (ATAC-seq),
bisulfite-sequencing and chromatin conformation capture (3C)-based highthroughput sequencing (Hi-C) technology.24,25
1.1.2 Epigenetics in cancer
Epigenetics plays a pivotal role in the normal physiological function or
development, and aberrant epigenetic regulation may be engaged in many
diseases including cancer.26 Recent advances have revealed global epigenetic
abnormalities in human cancers and reversing the dysregulated epigenetic
mechanisms could be a potentially effective targeted therapy.11
The first discovery linking epigenetic aberrations with cancer was identified
in the DNA hypomethylation in cancers back in 1983. Feinburg and Vogelstein
found that massive hypomethylation of CpG islands in some genes of cancer cells
3

compared with their normal counterparts in two different cancer types.27 Some
oncogenes such as HRAS were affected by hypomethylation.28,29 DNA 5methylcytosine content was also found to be universally reduced in cancer, and its
level was intermediate between benign and metastatic lesions.30 Hypermethylation
of tumor suppressors was first identified in 1989 which showed RB gene
hypermethylation in retinoblastoma.31-33 Not only local or genome-wide abnormal
methylation and demethylation of DNA CpG islands, but also the malfunction of
associated enzymes play an important role in regulating the gene expression in
cancer. Somatic mutations in these DNA methyltransferase and methylationbinding proteins contribute to human malignancies.
Histone modifying enzymes transfer or remove chemical groups to aminoterminal tails of core histones.34 These modifications could directly regulate the
accessibility and transcription of the DNA regions around the histone protein, or
recruit chromatin remodeler or other complexes to re-shape the chromatin
architecture. Abnormal histone modifications induced by mutations of chromatinbinding proteins were frequently observed in various types of cancer, which may
initiate or promote cancer development by disrupting the balance between the
transcription-activating modifications such as H4K16ac, H3K27ac and H3K4me3
and transcription-repressing modifications including H3K27me3 and H3K9me3.35
For example, losses of acetylated Lysine 16 and trimethylated Lysine 20 on
histone H4 have been described as hallmarks of human cancers.36 Mutations of
methyltransferase SETD2 which lead to global loss of tri-methylate histone H3 at
Lysine 36 were also frequently reported in tumor cells.37
4

Mounting evidence shows that components of chromatin remodelers are
mutated or functionally dysregulated in many cancers, which may reprogram the
gene expression associated with oncogenes or tumor suppressors. One of the
most important complexes involved is SWI/SNF complex, also known as
BRG/BRM-associated factor (BAF) complex in human, can modulate histone-DNA
interaction and remodel chromatin nucleosomes in an ATP-dependent manner to
regulate gene expression.

17-19

Its core catalytic subunit BRG1 is frequently

referred to in the literature as tumor suppressor or tumor susceptibility gene in
various cancers including NSCLC.38-42 Loss of BRG1/SMARCA4 may promote
cancer due to genomic instability, abnormal Myc signaling, uncontrolled cell cycle
or deficits in DNA repair.43-47 However, overexpression of BRG1 without apparent
mutation emerges as oncogenic mechanisms, which might involve the
RAS/RAF/MAPK, JNK, PI3K/Akt and Jak/STAT signaling pathways, in leukemia,
gastric carcinoma, breast cancer, prostate cancer and other cancer types,
demonstrating the dual faceted functionality of BRG1 in different cellular
contexts.48
Only a small number of transcribed genes are eventually translated, and the
remaining noncoding RNAs are believed to be essential for normal cellular
functions and their abnormalities potentially contribute to cancer or other
diseases.49-51 Noncoding RNAs regulate cancer initiation or progression by
transcriptional and post-translational alterations, chromatin reorganization and
disrupted signaling transmission. For example, HOX transcript antisense RNA
(HOTAIR) has been observed amplified in colorectal, lung and breast cancers,
5

mechanistically by coordinating with Polycomb Repressive Complex 2 (PRC2),
histone demethylase LSD1-containing CoREST/REST complex or other
microRNAs.52-55 Inhibition of HOTAIR was found to suppress PI3K/AKT/mTOR
signaling pathway and thus conferred sensitivity to imatinib.56,57 Together, these
findings demonstrate that various epigenetic regulators are deregulated or
mutated in cancers, which also shed light on therapeutic strategies targeting the
epigenetic aberrations.

1.2

Polycomb Repressive Complex 2 and cancer
1.2.1 Functions of PRC2
Gene expression is robustly and precisely regulated by transcription factors

in concert with chromatin-associated modifying complexes. Polycomb group
proteins, first identified in Drosophila melanogaster and conserved in mammalian
cells, play a vital role in this regulating process.58 Polycomb group proteins usually
assemble and form bulky complexes when exerting their normal functions, which
can be classified as two main categories, Polycomb Repressive Complex 1
(PRC1) and Polycomb Repressive Complex 2 (PRC2).59 Canonical and noncanonical PRC1 both contain the really interesting new gene 1A/B (RING1A/B),
which has the E3 ubiquitin ligase activity.60,61 PRC1 subunits also include
Chromobox (CBX) protein, polyhomeotic-like protein (PHC), Polycomb group
RING finger (PCGF) protein and other subunits depending on the variants.58 The
function of PRC1 is to mono-ubiquitinate histone H2A at Lys 119 (H2AK119ub).
6

PRC2 core proteins are composed of the enhancer of zeste homologue 2 (EZH2)
or its paralogue EZH1, embryonic ectoderm development (EED), suppressor of
zeste 12 (SUZ12) and RB binding protein 4/7 (RBBP4/7).62,63 Recent research also
identified that there exist four variants of PRC2 combining with different accessory
components, including elongin BC and PRC2-associated protein (EPOP)containing PRC2.1, PRC2-associated ligand-dependent corepressor isoform 1
(PALI1)-containing PRC2.1, adipocyte enhancer-binding protein 2–Jumonji AT
rich interactive domain 2 (AEBP2-JARID2)-containing PRC2.2 and Catalytic
Antagonist of Polycomb (CATACOMB)-containing PRC2 variant.58,64 These
variants may exert their functions at distinct cellular contexts, although PRC2.1
and PRC2.2 showed co-occupancy at most target sites.
Core subunit EZH2 contains a C-terminal SET-domain and acts as the main
lysine methyltransferase of PRC2, which could mono-methylate, di-methylate, and
tri-methylate histone H3 at Lysine 27 (H3K27me1, H3K27me2 and H3K27me3) by
using S-adenosyl methionine (SAM) as the methyl donor.65 EZH1 exhibits much
weaker methyltransferase activity and may target different downstream genes.66
EED recognizes and binds to the H3K27me3, stabilizing the catalytic function of
SET domain. The role of SUZ12 in PRC2 has not yet been completely understood.
Its zinc-finger may combine with HOTAIR to suppress gene expression.67
H3K27me3 is the most studied enzymatic substrate of PRC2 because its
distribution heavily overlaps with PRC2 binding sites. While histone H3 tail with
H3K27me3 remains positively charged and keeps the negatively charged DNA coil
tightly packed, loss of methyl groups or addition of acetyl groups to the histone tail
7

(H3K27ac) neutralizes the positive charges, making this genomic region more
accessible to transcription factors.
The balance of H3K27 methylation is orchestrated between the writers
(PRC2 proteins) and erasers (demethylases) of methyl groups. Two major H3K27
demethylases are the ubiquitously transcribed tetratricopeptide repeat X
chromosome (UTX/KDM6A) and Jumonji D3 (JMJD3/KDM6B), which can
discharge methyl groups from H3K27me3 and H3K27me2.68,69 The enzymatic
function of KDM6A/B is required for cell differentiation, embryonic or tissue
development and maintenance of the immune system. Abnormalities of H3K27
demethylases can also contribute to human diseases including cancer.70,71

1.2.2 PRC2 in cancer and epigenetics
PRC2 exhibits a key role in embryonic development and maintenance of
cell identity and may act as an oncogene or tumor suppressor in different cellular
contexts.72 Deletion of PRC2 core subunits in mouse embryos led to differentiation
and

development

defects,

such

as

gastrulation.73-75

Cancer-associated

perturbations of PRC2 include both activating and loss-of-function mutations in
EZH2, loss of function mutations in H3K27 demethylase genes KDM6A/B, and
H3K27M mutations and dysregulation of the SWI/SNF chromatin remodeling
complex, which is a PRC2 antagonist.76-78 Initially reported in Hodgkin’s
lymphoma, the first study linking PRC2 proteins to cancer was in prostate cancer
in 2002.79,80 It found EZH2 was overexpressed in hormone-resistant metastatic
8

prostate cancer and knockdown of EZH2 reduced cell proliferation. Many
subsequent studies have shown that high levels of EZH2 correlated with worse
prognosis in cancer types including breast and lung cancers, and enforced EZH2
expression is oncogenic in the lung and drives sensitivity to pharmacological
inhibition of EZH2.81-83 In addition to high expression of EZH2, hyperactivating
mutation of EZH2 was first identified in follicular lymphoma.84 Gain-of-function
mutations of EZH2 were also observed in diffuse large B-cell lymphoma, NonHodgkin lymphoma and melanoma, frequently in Y646 or A682 sites of the SET
domain.85-87 The mechanism of activating mutant EZH2 observed in various
lymphomas might be due to its critical role in the formation of germinal center,
which retained GC B cells in a de-differentiation state and promoted the
lymphomagenesis.88,89 Other potential mechanisms include repression of pRBE2F tumor suppressing pathway, cell cycle and DNA repair-associated genes.90-92
However, several studies have also observed loss-of-function mutations of
PRC2 components, underlining the complex role EZH2 plays in tumorigenesis. It
was first reported in myelodysplastic syndromes (MDS) in 2010, which showed
that the patients harbored EZH2 chromosome 7q acquired anomalies.93,94
Dysfunction of PRC2 core proteins have also been observed in hematopoietic
neoplasms acute or chronic myeloid leukemia (AML/CML) and T-cell
lymphoblastic leukemia, as well as in solid tumors including malignant peripheral
nerve sheath tumor (MPNST).95-98 Partially deficient Polycomb activity was shown
to accelerate the proliferation of hematopoietic stem cells.99 Although no somatic
mutations of PRC2 subunits were observed in lung cancer, research showed that
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deletion of the PRC2 component Eed enhanced malignancy in KRAS+/Trp53-null
lung cancers by driving aggressive mucinous tumors and changing the tumor
immune microenvironment, supporting a role of PRC2 as a tumor suppressor in
lung adenocarcinomas.100 Likewise, deletion of Ezh2 in the context of oncogenic
KRAS and intact Trp53 drove aggressive lung cancers and exacerbated immune
cell infiltration.101 Collaborating with NF1 mutations, SUZ12 also acted as a tumor
suppressor in melanoma, high-grade glioma, and paranasal sinus (PNS)
cancer.95,102 Moreover, recent studies discovered a novel mutation H3K27M in
diffuse intrinsic pontine glioma (DIPG).103,104 DIPG with H3 Lys27-to-methionine
mutation resulted in global loss of H3K27me3, representing a newly recognized
and aggressive subtype of cancer in the WHO classification. Removal of H3K27M
reinstituted H3K27me2/me3 and impeded formation of murine glioma, suggesting
the tumor suppressive role of PRC2.105 Deregulation of H3K27 demethylases
KDM6A and KDM6B, or H3K27 acetyltransferases CREBBP and EP300 were also
detected in bladder cancer, urothelial carcinoma, T-ALL, Hodgkin’s lymphoma and
other cancers.106-110
In addition to the canonical methyltransferase activity of PRC2, EZH2
harbors non-canonical functions independent of Polycomb catalytic activity. In
castration-resistant prostate cancer (CRPC), EZH2 exhibited a functional switch
from methyltransferase to an activator of transcription factor androgen receptor
(AR).111 Such a switch required phosphorylation of EZH2. In ER-negative breast
cancer, EZH2 could transcriptionally stimulate NF-κB target gene expression
outside of the PRC2 complex.112 JAK3-induced phosphorylation of EZH2 also
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mediated a switch to transcriptional activator in NK/T-cell lymphoma.113 Besides,
EZH2 could also directly methylate non-histone substrates without other PRC2
proteins, such as GATA4, RORα, STAT3 and Talin1 proteins.114-118 In the
scenarios above, inhibition of only PRC2 enzymatic function may not be
mechanistically sufficient to retard tumor growth.
Increasing evidence manifests that chromatin remodeler SWI/SNF complex
has an antagonistic effect against PRC2 and affects its normal function in cancer.77
Loss of SWI/SNF core subunits SMARCA4 or SMARCB1 altered H3K27
methylation landscape due to absent PRC2 opposing by perturbed SWI/SNF
complex and fostered an oncogenic high-methylation status in malignant rhabdoid
tumors.119,120 Similar antagonism was also observed in epithelioid sarcoma and
atypical chordoma. Inhibition of PRC2 has been demonstrated a synthetic lethality
on tumors with loss-of-function mutations of SWI/SNF components in many
cancers.121,122 Collectively, PRC2 plays divergent roles in different cellular contexts
of cancer through distinct mechanisms, which requires comprehensive
characterization.
1.3

Targeted therapies in non-small cell lung cancer
1.3.1 Non-small cell lung cancer and current therapies
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related

death worldwide, which mainly comprises lung adenocarcinoma, squamous cell
carcinoma

and

large

cell

carcinoma.123,124

Chemotherapy,

radiotherapy,

immunotherapy and targeted therapy provide different options to late-stage
metastatic lung cancer patients. Although the molecular studies of NSCLC
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identified targetable mutations of some oncogenes and tumor suppressors, no
mutation-guided targeted therapies exist for the majority of cases.125,126
Gain-of-function mutation of epidermal growth factor receptor (EGFR) was
the first targetable driver mutation discovered in lung cancer, which could be
targeted by EGFR-tyrosine kinase inhibitors (TKIs).127,128 The current druggable
targets also include anaplastic lymphoma kinase (ALK) and ROS1 gene
rearrangements, BRAF V600E mutations, neurotrophic receptor tyrosine kinase
(NTRK) 1/2/3 gene fusion, KRAS mutations, MET alterations and RET
translocations.129,130 Some other promising molecular targets are currently under
clinical studies, including human epidermal growth factor receptor (HER-2)/ERBB2
mutations.
The EGFR TKIs harbor different generations of drugs with distinct
mechanisms of action, including first-generation reversible TKIs erlotinib and
gefitinib, second-generation irreversible inhibitors afatinib and dacomitinib, and
third-generation mutation-selective inhibitor osimertinib.131-133 Osimertinib recently
was approved by FDA as the first line agent, which could irreversibly bind to
acquired EGFR T790M mutation as well as exon 21 L858R mutation and exon 19
deletion.134,135 The first-generation ALK TKI crizotinib, which acts on both ALK and
ROS1 translocations, was approved by FDA based on clinical trials PROFILE
1001, 1005, 1007 and 1014.136-139 Patients resistant to crizotinib, especially with
central neural system (CNS) metastasis due to its inability to cross blood-brain
barrier, are recommended to use second-generation TKIs ceritinib and alectinib,
or third-generation lorlatinib.140-143 Currently, alectinib is the preferred first-line
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agent for ALK-positive patients, while crizotinib is still the favored option for NSCLC
patients with ROS1 gene rearrangement.144-146 Another first-line therapy for ROS1positive patients is entrectinib.147 BRAF protein plays an important role in
MAPK/ERK signaling pathway, and its most common mutation is BRAF V600E.148150

The first-line treatment is recommended dabrafenib combined with traiminib.151

Vemurafenib, the first FDA-approved BRAF V600E inhibitor in melanoma, was
currently studied in a phase 2 clinical trial for NSCLC.152-154 MET exon 14 skipping
or amplification leads to constitutive activation of MET receptor tyrosine kinase.155
Based on GEOMETRY NONO-1 clinical trial, capmatinib was approved by FDA
for MET mutant or amplified NSCLC patients.156 Gain-of-function fusion mutations
of RET enhance its signal transduction and are associated with many cancers,
which can be targeted by FDA-approved selpercatinib or pralsetinib.157-159
Similarly, entrectinib and larotrectinib could target fusion gene of NTRK.160 Most
excitingly, the recent results from CodeBreaK100 study exhibited effectiveness of
sotorasib (AMG510) in NSCLC patients with KRAS G12C mutation.161,162 KRAS
mutation, one of the most frequent mutations in lung cancer, activates
RAF/MEK/ERK downstream pathways and drastically promotes the tumor
growth.163 FDA granted a priority review designation for sotorasib which sheds light
on the potentially first agent for KRAS mutations.
Recent advances on the targeted therapies dramatically alter the landscape
of systemic therapeutics of lung cancer and pave the way for precision medicines
of NSCLC patients. Future directions of targeted therapies are focused on the
discoveries of novel molecular targets and development of new drugs or
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combination therapies to enhance efficacy or overcome the acquired resistance to
current treatments.
1.3.2 EGFR in lung cancer
EGFR/ErbB1/Her1 is the first discovered receptor tyrosine kinase in erbB
family, which also contains ErbB2/Her2, ErbB3/Her3 and ErbB4/Her4.164,165
Epidermal growth factor or other specific ligands binding to EGFR drives its homoand/or hetero-dimerization, auto-phosphorylation of the intracellular tyrosine
kinase (TK) domain and downstream signaling transduction, which includes
subsequent

activation of

Ras/Raf/MEK/ERK,

PI3K/AKT/mTOR or

signal

transducer and activator of transcription (STAT) pathways.166-168 Somatic
mutations in the EGFR TK domain were first identified in NSCLC in 2004, which
resulted in its ligand-independent activation.127,128 Exon 19 deletion, exon 21
L858R point mutation and exon 20 insertion are the most common mutations of
EGFR.169,170 EGFR is mutated in about 10-20% of lung cancer patients of
Caucasians, while it is more frequently mutated in Asian lung cancer patients
(around 30-50%), especially in female non-smokers.171,172
Inhibition of the enzymatic activity of EGFR tyrosine kinase has been one
of the most successful targeted therapies in cancer. Gefitinib, the first FDAapproved EGFR TKI for lung cancer in 2003, competitively occupies the adenosine
triphosphate (ATP)-binding site in TK domain and interrupts its signal
transduction.127,128 Another first-generation reversible TKI erlotinib was then
approved in 2004.173 Unfortunately, almost all patients developed resistance to
TKIs eventually due to acquired secondary mutations.174,175 Substitution of
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methionine for threonine on codon 790 (T790M) is the most common reason of
acquired resistance, which promoted the emergence of second- and thirdgeneration TKIs binding to C797 in the TK domain.176-178 However, newly acquired
resistance were observed in osimertinib-treated lung cancer patients, usually
resulting from EGFR mutations (C797S, G724S, L718Q), loss of T790M, pathway
bypass through KRAS, MET or PIK3CA activation or small-cell lung cancer
transformation.179-181 Therefore, combinatorial strategies or optimizing the
selection of patients may enhance and prolong the responses of TKIs.

1.3.3 PI3K in lung cancer
PI3K/AKT/mTOR pathway is frequently altered in diverse types of cancers,
including NSCLC.182 PI3K, which represents the phosphoinositide 3-kinase, is an
intracellular lipid kinase capable of phosphorylating 3’ hydroxyl groups of
phosphatidylinositol.183,184 The PI3K family contains four classes, and PIK3CA
gene encoding class IA PI3K p110α catalytic subunit is mutated or amplified in
breast, liver, cervical cancer and lung cancer.185-188 The p100α subunit mutations
most commonly occur at exon 9 E545K, followed by exon 20 H1047R and exon
9E542K. PIK3CA E545K and E542K mutations in the helical domain unleash the
p110α inactivation by the regulatory subunit p85, while H1047R mutation in the
catalytic domain enhances the membrane interaction capacity of p110α.189-191
Deregulation of Other oncogenic driver mutations including KRAS or EGFR coexist with PI3K aberrations and could also trigger PI3K pathway activation.192
Phosphatase and tensin homolog (PTEN) dephosphorylates PIP3 to PIP2 and acts
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as a negative regulator of the PI3K pathway.193-196 Reduced PTEN function by
PTEN inactivating mutation, deletion or transcriptional suppression could also
stimulate PI3K/AKT/mTOR pathway.197,198 Mechanistically, abnormalities of PI3K
or PTEN lead to phosphorylated AKT by phosphoinositide-dependent kinase-1
(PDK1),

which

subsequently

regulates

cell

cycle,

apoptosis

and

cell

proliferation.199,200 Activated AKT also phosphorylates tuberous sclerosis complex
1/2 (TSC1/2), which in turn stimulates mTOR and its downstream 4E-BP1 and
S6K-1, promoting tumor growth and metabolism.201,202
Several PI3K inhibitors have been approved by FDA, which includes
copanlisib for relapsed follicular lymphoma, alpelisib for hormone receptor (HR)positive, HER2-negative, PIK3CA mutant breast cancer.203,204 Although currently
no PI3K inhibitors are approved for lung cancer, promising preclinical studies and
clinical trials of PI3K inhibitors as well as AKT and mTOR inhibitors are in
progress.182 Given the modest cytotoxic effect of PI3K inhibitor alone and bypass
through alternative upstream or downstream pathways, combination treatments
may enhance the efficacy of PI3K inhibitors in NSCLC.

1.4

Technological advances for 3-dimensional organotypic culture
Mouse models with genetic- or carcinogen-induced transformation are used

extensively to study autochthonous lung cancers and are considered outstanding
preclinical models. However, use of mice for research is costly, time-consuming
and comes with ethical concerns. Therefore, establishing reproducible ex vivo
models of lung cancer initiation and progression is important for the field. While
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traditional two-dimensional (2D) cultures can be propagated successfully for some
murine primary cancer cells in vitro, many genotypes of murine-derived tumors are
not able to thrive in classic 2D culture scenarios. In our experience, 2D cell lines
are very difficult to establish from murine tumors with Kras mutation

205

, Egfr

mutation 206, Kras mutation/Lkb1-loss 207 or Lkb1-loss/Pten-loss 208. Nevertheless,
three-dimensional (3D) culture, which simulates the spatial properties of in vivo
circumstances and has been applied to cultivate lung stem/progenitor cells 209-213,
can be used to propagate these distinct transformed lung cells in vitro 208,214.

There are various cell and tissue culture platforms for normal lung epithelial
cells

215,216

. Conventional 2D monolayer culture fails to maintain the capacity of

long-term growth and differentiation into other lineages

217,218

. 2D air-liquid

interface (ALI) culture has been exploited to induce human bronchial epithelial cells
(HBEC) to differentiate into mucociliary cells, albeit lack of complex tissue
architectures 219-221. It has also been difficult to reproducibly differentiate basal cells
in 2D-ALI culture 209. 3D-submerged culture utilized Matrigel as a substrate, which
comprises laminin, fibronectin, collagen and other structural proteins, to
investigate the multi-cellular differentiation and branching morphogenesis of
epithelial stem cells

222-224

. The 3D-ALI organoid culture combines the former two

systems with specialized media aiming to sustain physiological microenvironment
of lung epithelial cells, including the respiratory airway anatomy and hormones
circulating in the bloodstream

211,213

. In addition to normal airway organoids, this
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technique is also employed to model cystic fibrosis, pulmonary infection and lung
cancer 216,225.

3D-ALI cultures not only provide an achievable way to model the tumors in
vitro that could not propagate in conventional 2D cultures, but also more faithfully
recapitulate the pathophysiological structures, function and gene expression of in
vivo diseases. A recent study using CRISPR-based screen showed that pathways
associated with DNA replication or other essential cellular functions were enriched
in 2D human lung cancer lines, while cancer-specific pathways, including RAS and
p53 pathways, were enriched in 3D spheroid culture, consistent with the belief that
3D cultures are able to retain more characteristics of the native tissue from which
they were derived

226

. Co-culturing of tumor cells with endothelial cells,

lymphocytes or other elements from the extracellular niche is also feasible in the
3D organoid culture

227,228

. Furthermore, the mammalian lung is a complex organ

containing distinct stem/progenitor cell populations in various genetic and
microenvironmental contexts, which includes basal cells and club cells in the
proximal airways, bronchioalveolar stem cells (BASCs) and alveolar type 2 (AT2)
cells in the distal airways.

213,229,230

To interrogate which may cells serve as cells-

of-origin for lung carcinomas, one can pre-sort differing lung cell populations and
genetically modify these lung cells ex vivo prior to organoid seeding. This system
also allows examination of the earliest changes during the tumorigenesis. Given
the resemblances to in vivo, organoid cultures could exert encouraging potentials
in clinical drug testing, particularly the epigenetic therapies 231.
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So far, murine tumor organoids have been employed in diverse lung cancer
research. Several studies have used isolated ‘normal’ lung cells, genetically
modified these cells in vitro, and subsequently demonstrated the ability of these
populations to transplant bona fide lung cancer

214,232,233

. These types of

experiments allow for careful examination of the phenotypes associated with each
genetic manipulation. For example, organoid cultures were used to elucidate the
effect of FAK inhibition on cell invasion in Lkb1-deleted lung epithelial organoid
cultures

234

. Another study discovered BCL11A as an oncogene that could drive

squamous-like phenotypes in mouse tracheal-derived organoids

235

. Established

lung tumors have also been used to discover new facets of disease. 3D culture
has served as a surrogate in vitro assessment for tumor propagation efficiency of
differing subpopulations of murine tumor cells

208,236,237

. As another surrogate

assay to in vivo testing, effects of epigenetic inhibitors have been demonstrated
on lung-tumor derived organoids

214,238

.

Finally, murine-derived lung tumor

organoids were also recently used to test dynamic responses to immune
checkpoint inhibitors and MEK inhibitors 239,240.

Although murine organoid cultures have recently gained popularity, there is
currently no well-defined protocol in the literature for production of genetically
modified murine lung organoids, which may impede dissemination and
development of this technique. In the following studies described in this
dissertation, we utilize a validated and detailed experimental method to establish
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and propagate benign or malignant genetically modified lung organoids in 3D-ALI
culture for cancer- and stem cell-related research.

1.5

Goal of the projects
The goal of the three projects described below focus on the study of

epigenetic regulations in the tumorigenesis, progression, and therapeutic
sensitivities to targeted therapies in non-small cell lung cancer. Cancer
epigenetics, especially Polycomb Repressive Complex 2 (PRC2) have been
shown deregulated in cancer research, and the inhibition of PRC2 function has
been used in clinics. Therefore, understanding the role of epigenetic regulators in
lung cancer and cancer stem cells is uniquely important for physicians and
scientists to guide treatments on patients and also discover promising combination
strategies.
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CHAPTER 2. MATERIALS AND METHODS
2.1

Cell lines
Cell culture experiments were done in accordance with Institutional

biosafety regulations. All human cell lines except HBEC3KT were maintained in
RPMI 1640 media (Gibco, #11875-093) with 10% fetal bovine serum (VWR), 4mM
L-glutamine (Gibco, #35050-061) and penicillin/streptomycin (Gibco) at 37°C, 5%
CO2. A549, H460, H2030, H2009, H1975 and PC9-GR4 cells were obtained from
the laboratory of Dr. Carla Kim at Boston Children’s Hospital, BEAS2B cells were
a kind gift from Dr. Chengfeng Yang at University of Kentucky, and HBEC3KT cells
241

were a kind gift from Dr. David Orren at University of Kentucky. HBECK3KT

cells were seeded onto gelatin pre-coated plate and maintained in PneumaCultEx Basal media (StemCell Tech, #05009) with PneumaCult-Ex Supplement
(StemCell

Tech,

#05019),

Hydrocortisone

(Sigma,

#H0888)

and

penicillin/streptomycin at 37°C, 5% CO2. All human lines were verified by STR
genotyping at IDEXX laboratories at the beginning of the studies and no
mycoplasma was detected in cultures by MycoAlert Mycoplasma Detection Kit
(Lonza). Plasmocin (InvivoGen, #ant-mpt) was added into cultures regularly.
Mouse primary 2D cells were obtained by plating freshly dissociated mouse tumors
on tissue culture plates and passaging cells that adhered and grew. These cultures
were maintained in DMEM F-12 media (Gibco, #11330-032) with 10% fetal bovine
serum, 1% Insulin-Transferrin-Selenium (Corning, #25800CR), 4mM L-glutamine,
penicillin/streptomycin and plasmocin at 37°C, 5% CO2. For three-dimensional
Matrigel culture of primary cells, see below Tumor Cell 3D Culture.

2.2

Animals
All care and treatment of experimental animals were in accordance with

Boston Children’s Hospital and University of Kentucky institutional animal care and
use committee (IACUC) guidelines. For Chapter 3, cohorts of LSL:KrasG12D/+;
Trp53flox/flox; Ezh2flox/flox (LSL: lox-stop-lox) genetically modified mouse models
242,243

were maintained in virus-free conditions on a mixed C57BL/6x129SVj

background. Mice were bred predominately as Ezh2fl/+ so that littermates and close
relatives of the three Ezh2 genotypes could be analyzed for differential survival,
metastasis, and tumor burden studies. For survival, mice that had healthy body
characteristics at time of sacrifice were excluded from analysis. Both male and
female mice were used for all experiments and no sex differences were noted.
Adult mice received 2.5-2.9 x 107 PFU adeno-Cre. Mice were evaluated by
Magnetic resonance imaging (MRI) 12 weeks after adeno-Cre infection for
baseline scans. For Kras/Trp53/Ezh2 mouse models, JQ1 in aqueous suspension
were made by diluting DMSO stock dropwise with + 1:1 v/v Captisol in sterile saline
while vortexing and was i.p. injected at 50mg/kg q.d. for 2 weeks. For Nude mouse
allograft experiment, Kras/Trp53/Ezh2 mouse tumor spheroids were dissociated
into single cells, counted, and resuspended at 1×105 cells per 200μL of 1:1
media/Matrigel (Corning, #356231). Female Athymic Nude Foxn1Nu/Nu mice
(Envigo) were injected subcutaneously with 1×105 cells in 2-4 spots on flanks.
Tumors were allowed to grow for 21 days to a mean size of 60mm3. Mice were
then randomized into groups that received GSK-J4, JQ1 or vehicle. 100mg/kg
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GSK-J4 or 50mg/kg JQ1 dissolved with 100% DMSO were administered by i.p.
injection q.d. for 10 consecutive days. Tumors were measured by electronic caliper
and tumor diameters were used to calculate tumor volumes (Tumor volume= (π x
length x width2) / 6). For Chapter 4, the PIK3CA mouse strain was a kind gift from
Dr. Susanne Baker at St. Jude’s (Roy, Millen, eLife 2015). The mice were crossed
to produce offspring with Pik3ca-E545K

LSL/+

;Trp53

fl/fl

cohorts.244 Induction of

medulloblastomas in Trp53-null mutant mice by somatic inactivation of Rb in the
external granular layer cells of the cerebellum. Mice were genotyped and
maintained in virus-free conditions with ad libitum food and water. After 6 weeks
of age, mice were anesthetized with ketamine/xylazine and adeno-Cre (University
of Iowa) was administered by intranasal instillation at a dosage of 2.9x106 PFU per
mouse.

Mice were monitored for any signs of lung tumor burden, including

hunched appearance or difficulty breathing. Mice were sacrificed for histological
lung analysis and to establish lung cancer organoid cultures. For xenograft assays,
Calu3 cells were implanted subcutaneously into Nude (Foxn1Nu/Nu) mice using
Matrigel. Tumor growth was monitored and when tumors reached an average of
100mm3, the mice were randomized to groups. Doses were EPZ-6438, dosed at
250mg/kg BID in sterile water, 0.5% sodium carboxymethylcellulose, 0.1% Tween
80 by gavage and copanlisib dosed at 14mg/kg in sterile water with 7% mannitol
by i.p. injection every other day.245-247 Tumors were measured daily by electronic
caliper and tumor volumes were calculated using the equation (length x width x
width/2). For chapter 5, Cohorts of both male and female mice were used for
autochthonous tumor experiments, and no sex differences were noted. Adult mice
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received 2.9 x 107 PFU adeno-Cre. Immunocompromised mice (Nude, Foxn1Nu/Nu)
were used for orthotopic intra-tracheal instillation with AdenoCre-treated
organoids, with 6 of which being excluded due to metastatic lymphoma or cardiac
tumor, or unexplained decease not related to tumors.

2.3

Patient samples
Patient slides were provided by the Markey Cancer Center Biospecimen

Procurement & Translational Pathology Shared Resource Facility (BPTP SRF) of
University of Kentucky. Discarded samples were obtained by BPTP with patient
informed consent or waiver under an IRB approved protocol, and when transferred
to our group, the samples had been de-identified and therefore exempt from further
Institution Review Board approval. The tissue microarray included 83 lung
adenocarcinomas (ADCs), 14 lung adenosquamous carcinomas (ADSCCs), 102
lung squamous cell carcinomas (SCCs) and 13 poorly differentiated tumors
including 1 sacromatoid tumor. For these cases, three core biopsies were removed
from a larger tumor piece and arrayed on slides. To increase sample size, we also
used whole tumor slides from an additional 9 ADCs, 10 ADSCCs and 2 SCCs.
Four tumors on the TMA, one giant cell carcinoma, two large cell neuroendocrine
and one pleomorphic carcinoma were excluded from the analysis as they did not
fit well with any major histological group.
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2.4

Flow cytometry analysis and sorting
Tumors were dissected from the lungs of primary mice and tumor tissue

was chop extremely finely with surgical scissors. Tumor chunks were incubated
with 1mL 1x PBS with 60µL Collagenase/Dispase (Sigma, #10269638001) in a
rotator at 37oC for 30min. After washed with 1X PBS, chunks were resuspended
in 100µL 0.25% Trypsin-EDTA (Gibco) for 2min, then neutralized with 900µL PBS
containing 10% FBS (PF10). Next, the digested tissue was filtered through a
100µm filter (VWR), then a 40µm filter (VWR) into a 50cc conical tube. Cell pellets
were resuspended in 100µL Red Cell Lysis buffer (0.15 M NH4Cl, 10mM KHCO3,
0.1 mM EDTA, in 1L distilled H2O; filtered with 0.45 µm filter and stored at RT) for
2min at RT and added 800µL PF10. Single cell suspensions were stained using
rat-anti-mouse antibodies including anti-mouse-EpCAM-PECy7 (BioLegend), antimouse-CD31-APC (BioLegend) and anti-mouse-CD45-APC (BioLegend), antiNGFR

(AbCAM

primary,

anti-rabbit-PE

secondary)

and

anti-Sca1/Ly6A

(BioLegend). Live cells were gated by exclusion of 4',6-diamidino-2-phenylindole
(DAPI) positive cells (Sigma, #D9542). All antibodies were incubated for 10-15
minutes at 1:50-1:100 dilutions for primary antibodies and 1:200 for secondary
antibodies. Cell sorting was performed with a Sony iCyt with an 100µm nozzle.

2.5

7AAD cell cell flow cytometry analysis
Cells propagated in 2-dimensional dishes or 3-dimensional transwells were

separated into single cells by 0.25% Trypsin. 1-10x105 cells were spun down in a
1.5mL microtube and resuspended in cold 300µL PF10. Then the resuspended
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cells were added dropwise to 700µL cold 70% Ethanol with slow vortexing and
were incubated at 4°C for least 1 hour. Cells were pelleted by pulse spin and
resuspended in 250µL/tube of 1mg/mL RNase A (Thermo Fisher, #EN0531)
diluted in PBS for 30min. Cells were washed by 1ml PBS, pelleted and
resuspended in 250µL/tube of 20μg/mL 7-Aminoactinomycin D (Invitrogen,
#A1310). 30,000 events/sample were collected on the BD LSRII and analyzed with
the ModFit LT software and results were averaged for 3 or 4 biological replicates.

2.6

MRI of genetically engineered mouse model
A Brucker ClinScan system that has 12 cm actively shielded gradients with

maximum strength of 630 mT/m and slew rate of 6300 T/m/s was used. The tumor
bearing mice were anesthetized by isoflurane inhalation, kept warm by a heating
pad and imaged on the 7T system with a 2x2 array coil with a 2D gradient echoT1weighted sequences with parameters: 18 slices, TR = 170 ms, TE = 2.4 ms, α=38°,
Navg=3, FOV 26 x 26 mm2, 1mm thickness, matrix size 256 x 256, for a voxel size
of 0.102 x 0.102 x 1.0 mm. Images were gated to the animal’s respiratory cycle
using a pneumatic respiratory monitor (SA Instruments) to remove breathing
motion artifacts. The cardiac cycle and temperature were monitored using SA
instruments hardware and software. The tumor burden volume and quantification
were reconstructed on 3D Slicer software (http://www.slicer.org).

26

2.7

Tumor cell 3D culture
Mechanically and enzymatically dissociated tumor cells were resuspended

in DMEM/F12 media containing 1x penicillin/streptomycin, 4mM L-glutamine, 10%
fetal

bovine

serum,

10µg/mL

Insulin

(Sigma,

#I-6634),

1x

Insulin/transferrin/selenium mixture (Corning), 12.5µg/mL bovine pituitary extract
(Invitrogen, #13028-014), 0.1µg/mL cholera toxin (Sigma, #C8052), 25 ng/mL
mEGF (Invitrogen, #53003-018) and 25 ng/mL rmFGF2 (R+D Systems, #3139FB/CF), mixed 1:1 with growth factor-reduced Matrigel (Corning), and pipetted into
a 24-well 0.4 µm Transwell insert (Corning, #CLS3470). Tumor chunks or roughly
5,000 tumor cells were seeded into each well. MTEC/Plus (described above)
medium (500µL) was added to the lower chamber and refreshed every other day.
Tumor spheroids form usually in 10-14 days. To passage spheroids, media in the
lower chamber was aspirated, 100-150uL of Dispase (Corning, #42613-33-2) was
added over the top of well and the Matrigel was dislodged to be floating. After
incubation at 37°C for 1-2 hours, the Matrigel was liquefied and the spheroids were
pipetted into a tube for passage or other steps. Upon second and third passage,
more homogeneous spheroids should arise with little residual debris remaining.
Large and differentiated spheroids with dense squamous-like structures were
removed. EPZ-6438 (MCE, #HY-13803), GSK-J4 (MCE, #HY-15648B) and JQ1
(MCE, #HY-13030) were stocked as 10 mM solution in DMSO and were diluted
according to the designated concentration into tissue culture media for use. For
Chapter 4, BEAS2B stable cells were seeded in transwells (Corning) at a
concentration of 2X103 cells/well in a 1:1 mixture of 10% FBS containing RPMI
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1640 medium and phenol-red free, growth factor reduced Matrigel (Corning). A
volume of 500 µl of RPMI 1640 medium with 10% FBS was added to the bottom
of the plate and the culture medium was replenished every other day. The cells
were cultured for 3 weeks and the colony growth was imaged with Cytation5.
Organoids were quantified by counting on the images and confirmed by a blinded
user. Five independent replicate experiments were performed, and one was
excluded due to poor growth of the control EV cells compared to the other
experiments. For Chapter 5, cell infections were performed as described.248 Briefly,
sorted cells were incubated in 100µL of 6x107 pfu/mL adeno-Cre or adeno-GFP
virus (University of Iowa) in complex media for 1-2 hours at 37°C, 5% CO2. Cells
were then washed by pelleting and resuspending prior to being plated in transwells
with Matrigel and low passage neonatal lung mesenchymal support cells. The
EGFR organoids previously maintained in transwells of 24-W plates were
dispased, washed, digested with trypsin. Cells were seeded in 20 µl of Matrigel to
384-well Corning Spheroid microplates at 200-300 cells/well together with 5,000
cells/ well of mouse endothelial cells. A 10µl of medium was applied to the top of
Matrigel. After culturing for 3 days when there appeared noticeable organoids
under microscope, 20 ul of drug solutions were added to the wells. After treatment
for 3 days, cell viability was measured with CellTiter-Glo 3D (Promega). Briefly,
25µl of GellTiter-Glo 3D lysis buffer was added to each well. After being shacked
on a platform for 5 min and incubated at room temperature for 25min, the
luminescence signal was measured in Cytation5 luminometer. Values were
normalized to vehicle controls for each drug columns to yield percent survival, and
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drug doses converted to a log scale for graphing as log(inhibitor) vs. response –
variable slope (four parameters). Bottoms were constrained to zero. P values
comparing IC50 values were extracted and corrected with Holm-Sidak p value
adjustment for each drug.

2.8

Cell viability assay
Cell lines were dissociated, counted, and plated 50µL media with 2000 cells

(for human cells) or 5000 cells (for mouse cells) per well in 96-well plates. Edge
wells were filled with 135 µL PBS. 50µL media with different concentrations of
drugs EPZ-6438, GSK-J4, JQ1, carboplatin (Sigma, #C2538), etoposide,
copanlisib, and osimertinib were added after 24 hours. After 96 hours, 50µL
CellTiter-Glo (Promega, #G7573) was added into each well and the chemical
luminescence was measured on a BioTek Cytation 5. Results from independent
experiments were entered into the GraphPad Prism software to extrapolate IC50
and p values using non-linear regression least squares fit of response vs.
log(inhibitor) or normalized response vs. log(inhibitor). For the murine cell line
response to GSK-J4, log(agonist) vs. response is shown as that model fit the data
the best. For synergy assays, combinations of different doses were added into 96well plates as synergy matrix and measured by CellTiter-Glo. The percentage
survival for each well compared to the control well were uploaded to
https://synergyfinder.fimm.fi/ to calculate Bliss synergy score (readout: viability;
baseline correction: yes) and display 3D synergy heatmap (>1 means
synergism).249 For chapter 3, the Bliss score was calculated by the averaged
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percentage of each dose. For chapter 4 and chapter 5, the 95% confidence interval
of Bliss score was calculated by uploading 3 or 4 technical replicates.

2.9

Soft agar transformation assay
The soft agar transformation assay was administered following the protocol

described in with minor modifications.250 Pre-warmed medium (DMEM + 20% FBS
+ 1% P/S) was mixed with and the autoclaved 1.2% agarose solution (Sigma,
#A9539) at volume ratio 1:1 thoroughly. 2 mL of the mixed solution was dispensed
into each well of 6-well plate and wait for 1-2 hours to allow it to solidify. Cells were
isolated, counted and 5000 cells were mixed with 1 mL of the 0.8% low melting
agarose (Lonza, #50101) solution and 1 mL of pre-warmed medium. The mixture
was dispensed into the 6-well plate which contained already solidified bottom layer
of agarose. Then the plate was transferred to 4°C for 30 minutes to help
solidification. 2mL of DMEM with 10% FBS + 1% P/S was added to each dish and
was placed in the 37°C incubator. Images were taken after 3-4 weeks.

2.10 Crystal violet growth assay
Cell lines were dissociated, counted and 1mL media with 1000 cells per well
was seeded into 12-well plates, 3 wells/plate in 4 plates per sample. The 4 plates
were marked as Day 0, Day 2, Day 4, and Day 6. 6-8 hours after seeding, media
was aspirated and cells in the Day 0 plate were fixed with 10% neutral buffered
formalin per well for 30 minutes RT. After removal of formalin, the plates were
washed with water 2-3 times and was let dry inverted. Same procedures were done
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every other day on Day 2, Day 4 and Day 6 plates. After Day 6, all the 4 plates
were stained with 400 µL crystal violet solution (1g crystal violet (0.5%, VWR
#97061-850), 150 mL ddH20, 50 mL methanol) for at least 30 minutes. Then the
crystal violet solution was disposed, and the plates were washed with water 3 times
and dried inverted. The stained crystal violet was then released into solution with
400 µL 10% glacial acetic acid (in water, Sigma #A-6283). 100 µL of the dissolved
crystal violet was aliquoted into a 96-well plate and was read by OD595 on Cytation
5.

2.11 Quantitative RT PCR and RNA-sequencing
RNA from treated cell lines was extracted using Absolutely RNA kits
(Agilent) and cDNA was made using the SuperScript III kit (Invitrogen). Relative
gene expression was assayed with Taqman probes (Thermo Fisher, #4318157)
on the Quant Studio 3™ Real-Time PCR System (Applied Biosystems). Relative
expression was calculated by Gene of Interest (Ctreference-Ctexprimental)-Housekeeping gene(Ctreference-Ctexperimental) and graphed on the log2 scale. House-keeping
genes were either GAPDH/Gapdh or ACTB/Actb (B-actin) (Applied Biosystems).
Statistics were performed on log2 data. Unless specifically indicated, the reference
Ct value was the average of Ct values from each culture and treatment for a given
experiment, allowing for plotting of relative mRNA levels among cultures. For RNAsequencing, 10,000-50,000 of freshly sorted tumors or 0.5-1 million of 2D or 3D
cultured cells were suspended in lysis buffer for RNA extraction (Agilent columns).
RNA was extracted by Agilent Nanoprep (3D and sorted tumors, Agilent #400753)
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or Microprep (2D cells, Agilent #400805) kit. Library preparation and sequencing
were sent to and performed by the University of Kentucky Oncogenomics Shared
Resource Facility or by Beijing Genomics Institute (BGI Group). For sorted tumor
cells, the Smart-SeqII low-input protocol was used. Sequencing reads were
trimmed and filtered using Trimmomatic (V0.39)

251

to remove adapters and low

quality reads. Reads from human and mouse samples were mapped to Ensembl
GRCh38 and GRCm38 transcripts annotation (release 82), respectively, using
RSEM
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. Gene expression data normalization and differential expression

analysis were performed using the R package edgeR
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. Significantly

up/downregulated genes were determined as fold change >= 2 and q-value < 0.05.
Results were graphed by bar plots or dot plots using normalized enrichment scores
and FDR q-value.

2.12 Principal component analysis (PCA)
For PCA, the transcripts per million (TPM) read counts of each transcript
were log-transformed using log of TPM + 1 (using the log1p function in R for
numerical stability), and then PCA decomposition was performed using the prcomp
R function

254

. Each sample was designated as either being from 2-dimensional

cultures (2D) or not (other). For each principal component (PC), the sample scores
between 2D and other were compared using ANOVA. To find transcripts with
statistically significant loadings on a PC, each transcript’s loadings in that PC were
tested. All other transcript’s loadings in all the other PCs were used to create a null
distribution of loadings, and then the number of loadings greater than the tested
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transcript’s loading value and in the same direction (positive or negative) counted,
and divided by the number of null loadings in that direction. This fraction is the
reported p-value for that transcripts loading in that PC. Transcript loadings values
were considered significant if they had a p-value <= 0.05. The log-transformed
TPM values of transcripts with significant loadings in PC3 were used to calculate
an information-theoretically-weighted correlation, where the raw Pearson
correlation value is weighted by the information content between the two samples
based on their Jaccard metric, and the fraction of entries that are consistently
present (non-zero TPM) and missing (zero TPM) between the two samples. The
weighted-correlation was then be used as a pseudo distance (1 - correlation) for
hierarchical clustering and ordering using the dendsort package

255

. Heatmaps of

the correlation were generated using ComplexHeatmap 256.

2.13 Gene ontology enrichment
Gene ontology (GO) enrichments of the PC3 associated genes was done
using a custom version of categoryCompare

257

. GO terms from all three of

biological process, molecular function and cellular component were tested
simultaneously. GO annotations to genes are based on mapping the Entrez Gene
IDs to GO terms in the Bioconductor packages org.Mm.eg.db and GO.db version
3.11.4. The false discovery rate correction was generated using the BenjaminiHochberg method. Only those GO terms with an FDR <= 0.05 and annotated to
two or more genes are reported. The top 40 GO terms by p value are listed in Table
3.1.
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2.14 Gene set enrichment analysis
For Chapter 3, GSEA was performed with GSEA version 4.0.3 (Broad
Institute) with rank-ordered gene lists generated using all log-fold change values.
Mouse_ENSEMBL_Gene_ID_to_Human_Orthologs_MSIGDB.v7.1.chip

was

used to map mouse genes to human orthologs. Databases queried included
Hallmarks (h.all.v7.1), Curated (c2.all.v7.1), BioCarta (c2.cp.biocarta.v7.1), KEGG
(c2.cp.kegg.v7.1), Reactome (c2.cp.reactome.v7.1), GO (c5.all.v7.1), Oncogenic
Signatures (c6.all.v7.1), and Immunologic Signatures (c7.all.v7.1). Gene
signatures that converged on common themes were selected for further analysis
and graphing of enrichment scores and FDRs for specific contrasts. For Chapter
5, gene set enrichment analysis was performed with GSEA version 4.1.0 with gene
expression vsd-normalized by DESeq2 R package. Mouse genes were mapped to
human

orthologs

by

Mouse-

ENSEMBL_Gene_ID_to_Human_Orthologs_MSIGDB.v7.4 chip and queried for
Hallmarks (h.all.v7.4) and Oncogenic signatures (c6.all.v7.4). Results were
graphed by bar plots using normalized enrichment scores and FDR q-values
(q<0.05 as significant difference).

2.15 Chromatin Immunoprecipitation and qPCR (ChIP-qPCR)
Tumor cells were resuspended in Buffer A from Covaris kit (Covaris,
#520154). Then cells were cross-linked with 11.1% formaldehyde for 5 min at RT,
quenched by Quenching buffer E, washed in cold PBS and pulse spun. Pellets
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were re-suspended in Lysis buffer B and rotated for 10min at 4ºC. Lysed nuclei
were washed with Wash buffer C, resuspended in Sonication buffer D3 and
sonicated with the Covaris M220 Focused-ultrasonicator to obtain chromatin
fragment lengths of 200-to-1500bp judged by a Bioanalyzer DNA High sensitivity
kit (Agilent #5067-4626). Fragmented chromatin was diluted in Sonication buffer
D3 and incubated overnight at 4ºC with FOXP2 (Sigma, #HPA000382), H3K27ac
(Abcam, #ab4729) or H3K27me3 (Millipore, #07-449) antibodies. Then 40µL
Protein A/G 1:1 mixed magnetic Dynabeads (Invitrogen) were added and rotated
at 4ºC for 2 hours. Immunoprecipitates were washed with cold ChIP buffer (1%
Triton X-100, 0.1% Deoxycholate, 50mM Tris-HCl pH 8.1, 150mM NaCl, 5mM
EDTA), High salt buffer (1% Triton X-100, 0.1% Deoxycholate, 50mM Tris-HCl pH
8.1, 500mM NaCl, 5mM EDTA), LiCl buffer (250mM LiCl, 0.5% IGEPAL, 0.5%
Deoxycholate, 10mM Tris-HCl pH 8.1, 1mM EDTA) and TE buffer (10 mM TrisHCl and 1 mM EDTA). Immunoprecipitated (or no IP input) DNA was incubated
with 50µL Elution buffer (1% SDS and 0.1M NaHCO3) in 55ºC water bath
overnight. The eluted DNA was treated with RNase A and Proteinase K, and
column purified with DNA clean and concentrator kit (Zymo Research, #D4014).
ChIP-qPCR was run with the Power SYBR reagents (Thermo Fisher, #100029284)
on the Quant Studio 3™ Real-Time PCR System for the mouse Foxp2/human
FOXP2 TSS, ATG and enhancer regions and mouse Gapdh/human GAPDH (3
biological or technical replicates). The Foxp2/FOXP2 ChIP-qPCR data were
normalized to Gapdh/GAPDH abundance by a delta(deltaCt) method to control for
relative DNA input for each sample.
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2.16 Western blotting
Whole cell extracts were made in RIPA buffer (0.5% Deoxycholate, 1%
IGEPAL-CA630, 0.1% sodium dodecyl sulfate, 150mM NaCl, 50mM Tris-8.1),
lysates were cleared by centrifugation, and protein concentrations were quantified
with the Pierce BCA Protein Assay Kit (Thermo Fisher, #23225). For Western
blotting, 1-60µg of protein extract per sample was denatured with heat and
reducing agents, separated on a 4-15% acrylamide gel (BioRad) and transferred
to nitrocellulose membranes (GE Healthcare, #10600002). Antibodies used for
Western blotting were: EZH2 (Cell Signaling, #5246s, 1:1000), SUZ12 (Active
Motif, #39357, 1:1000), EED (Millipore, 09-774, 1:500), Histone H3 (Abcam,
#ab1791, 1:5000), H3K27me3 (Cell Signaling, #9733s, 1:1000), FOXP2 (Sigma
#HPA000382 1:1000 for human sample, Abcam #ab16046 1:1000 for murine
sample), phospho-AKT (Cell Signaling, Cat#4060s, 1:2500), AKT (Cell Signaling,
Cat#4691s, 1:2500) all incubated overnight at 4ºC. Histone H3 was used as
loading control. All antibodies have detailed species validation available online
from vendors. Secondary anti-rabbit IgG, HRP-linked antibody (Novus #NB7160,
1:10000) was incubated for 1 hour at room temperature. After washing,
chemiluminescence was visualized with West Pico PLUS Chemiluminescent
Substrate (GE Healthcare) and exposure onto Hyperfilm (Amersham).
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2.17 Histology and immunohistochemistry
Mice were anesthetized, hearts were removed and the lung lobes were
inflated with neutral-buffered 10% formalin and fixed overnight at room
temperature, and then transferred to 70% ethanol, embedded in paraffin and
sectioned at 4-5 μm. Hematoxylin and eosin stains, Alcian Blue and Masson’s
Trichrome stains were performed in the Biospecimen Procurement & Translational
Pathology Shared Resource Facility (BPTP SRF) of the University of Kentucky
Markey Cancer Center or at Harvard Medical Center. For tumor burden analysis,
H&E stained slides were scanned with an Epson scanner and 2800-3200 dpi
resolution 48-bit color. Images were cropped, white space was masked, and
trachea/esophagus/lymph nodes were masked. Images were auto-contrasted and
saved as 16-Bit grayscale, then opened in ImageJ software. Threshold settings
were first set to cover all of the lung and measurements were taken, 0.0001-infinity.
Then auto threshold was set and modified if needed to exclude areas that were
heavily infiltrated with immune cells but not tumor and to exclude thickened
bronchi, and measurements were taken, 0.0001-infinity. The ratio of tumor to lung
was calculated for each mouse. For some mice, a representative lobe or residual
lung with many tumors intact or partially intact were used so that tumors could be
harvested for other analyses. Nuclear grade was determined by Dr. Roderick
Bronson at Harvard Medical School on a set of histology slides representing
tumors harvested 108 days or more past adeno-Cre. Descriptions for nuclear
grade criteria were previously published 242. Grade 5 criteria were not used. Grade
4 included the criteria listed in the original paper and the appearance of tumor cells

37

invading into normal tissue or into blood vessels. Immunohistochemistry was
performed with either Tris or Citrate buffer antigen retrieval in the Brainson
Laboratory or the BPTP SRF, and staining was visualized with brown DAB
substrate and counterstain was either Mayer’s or Harris’s hematoxylin. Slides were
batch stained to reduce variability. Scoring of H3K27me3, EZH2 and FOXP2
nuclear staining was performed with Nikon NIS-Elements AR software on 20x
images obtained in a blinded fashion. Regions of stroma (blood cells, vessels,
fibroblasts and connective tissue) were deleted from the images by hand in
Photoshop. Edited images containing predominately tumor nuclei were analyzed
using Nikon’s dark spot detection module on the blue channel at eight different
equally spaced intensity cutoffs, which represent increasing stringency for positive
IHC stain. Nuclei counted at intensities 4-8 were considered positive, while nuclei
counted at intensity 1 represented all nuclei for a given image. Percentage of
positive nuclei in bins 4-8 were calculated. For binning tumor samples in Figures
7d and 7e tumors with greater than 20% positive nuclei were considered ‘high’ for
EZH2 and tumors with greater than 40% positive nuclei were considered ‘high’ for
H3K27me3. Imaging was performed on a Nikon Ti-Eclipse inverted microscope.
Immunofluorescence staining were done as described previously 258. The slides of
tumors or organoids were immunostained with primary antibodies for CCSP, proSPC, Acetylated-tubulin, P63, SOX2, KRT5, MUC5ac and secondary antibodies
donkey anti-mouse/goat Alexa 488 (FITC), anti-mouse/rabbit/goat Alexa 594
(TRITC), anti-rabbit/goat Alexa 647 (Cy5), and mounted with ProLong Gold
Mounting media with DAPI. Fluorescence images were captured on Nikon Ti-
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Eclipse inverted microscope. Exposures and look-up-tables were matched for all
images of each stain at each magnification, with the exception of DAPI look-uptables that were set for best visualization.

2.18 Transwell cell migration assay
Migration assays were performed with 24-well transwell plates with 8.0µm
Pore (Corning, #CLS3422). Briefly, cells were typsinized into single cells by 0.25%
Trypsin-EDTA and counted. Then 1-5x105 cells in 100μl serum-free culture media
was added into the top chamber insert and incubate for 10min. The bottom
chamber was filled with 600μl media containing 10% FBS. After 24-hour
incubation, nonmigratory cells were removed with a cotton swab, and the migratory
cells were fixed with formalin for 10min, 70% Ethanol for 10min, stained with 0.2%
crystal violet for 10min and washed off with tap water. Ten 20x images of each
transwell were taken on BioTek Cytation 5, the numbers of crystal violet stained
cells were counted manually and the average number of cells per well was
calculated.

2.19 Viruses
The pLKO.1 EZH2 shRNA (TRCN0000040076 and TRCN0000040073) and
FOXP2 shRNA (TRCN0000426742, TRCN0000426178) construct clones were
purchased from SIGMA and the shGFP plasmid 12273 and pENTR-FOXP2
plasmid 47053 were available on Addgene

259

. The FOXP2 over-expression

construct was flipped into pLenti6.3/V5-DEST vector (Invitrogen). For BEAS-KP
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cell generation, KRASG12V and p53R175H lentiviruses were used 260. KRASG12V
was a kind gift from Aveo Pharmaceuticals and p53R175H was a kind gift from the
Kuperwasser laboratory at Tufts Medical Center. Lentivirus was packaged in
HEK293T cells with above vectors together with the packaging construct pCMV
DR8.2Dvpr and VSV-G-pseudotyped lentiviral vectors by FuGENE 6 (Promega,
#E2691), using established protocols

261

. Cell lines were infected with viral-

containing supernatant for a period of 4-8 hours. Infected cultures were selected
with puromycin (hairpins) or blasticidin (FOXP2 and p53R175H) 5 days post
infection. For BEAS2B cells in Chapter 4, KRASG12V and p53R175H lentiviruses
and PIK3CA retroviurses were used. KRAS-G12V was a kind gift from Aveo
Pharmaceuticals and p53-R175H was a kind gift from the Kuperwasser laboratory
at Tufts Medical Center.262 PIK3CA vectors were purchased from Addgene.263
Infected cultures were selected by puromycin (PIK3CA vectors), GFP-sorting
(KRAS-G12V) or blasticidin (p53-R175H). PCR for viral inserts was performed on
isolated genomic DNA using a 59°C annealing temperature with the following
primers:
PIK3CA F: 5' – CCATACGACGTGCCAGATTA – 3',
R: 5' – CCTCACGGAGGCATTCTAAA – 3',
P53 F: 5' – CCTCACGGAGGCATTCTAAA – 3',
R: 5' - GCTCGACGCTAGGATCTGAC - 3',
KRAS F: 5' - TAGAGGATCCACTAGTACCACCATG - 3',
R: 5' - GCTTCCTGTAGGAATCCTCTATTG - 3'
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2.20 Statistics and reproducibility
All graphed data were presented as mean ± standard error of the mean
(s.e.m.) unless otherwise noted. In boxplots, the center line shows the median
values while the bounds correspond to the first and third quartiles, and upper and
lower whiskers extend to the highest and lowest values, respectively. For mouse
experiments, the biological n represented individual donor mice, and often several
replicate experiments for each donor mouse were averaged to produce the
biological replicates. For human cell line experiments with the exception of
validation of FOXP2 over-expression by RT-qPCR (Supplementary Fig. 6a), at
least three independent replicate experiments were used to generate averaged
data. Unless indicated, p values represent 2-tailed Student’s t-test with equal
variance that were used to compare continuous outcomes between two
experimental groups. Where indicated, ANOVA with pairwise comparisons were
used for comparing multiple groups. ANOVA with repeated measures was used to
compare the tumor change at each time point in the tumor growth studies. Fisher’s
exact tests were used to compare binary outcomes between groups. Kaplan-Meier
curves and Mantel Cox log-rank tests were used for survival outcomes. Pearson’s
correlation coefficients were used to quantify correlations of marker expressions.
A p-value less than 0.05 was considered statistically significant. * represents pvalue <0.05, ** p-value <0.01 and *** p-value <0.001. Adjusted p-values are shown
for figure 5.12. Statistical analyses were carried out using Excel, GraphPad Prism
or SAS version 9.4. The RNA-sequencing data generated for Chapter 3 are
available at NCBI GEO database under accession number: GSE154689. Five
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sorted samples of varied genotypes were excluded due to questions about sorter
operation that day. Those additional data are available upon request.
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CHAPTER 3. POLYCOMB DEFICIENCY DRIVES A FOXP2-HIGH AGGRESSIVE
STATE TARGETABLE BY EPIGENETIC INHIBITORS

3.1

Brief introduction
Lung cancer is the leading cause of cancer-related death worldwide264.

More than 85% of cases are classified as non-small cell lung cancer (NSCLC),
among which adenocarcinoma (ADC), arising from distal lung epithelium, is the
dominant type265. While some advances have been made with targeted therapies
to driver mutations including KRASG12C, mutant EGFR and mutant ALK, a large
percentage of lung adenocarcinomas remain for which chemotherapy is the first
line of treatment165,266. Given the importance of chromatin biology in cancer, it
stands to reason that epigenetic inhibitors may offer an avenue to drive therapeutic
vulnerabilities for many cancer types, including lung adenocarcinomas267.
Enhancer of zeste homolog 2 (EZH2), the functional enzymatic component
of the Polycomb Repressive Complex 2 (PRC2), is best known as a histone
methyltransferase that tri-methylates histone H3 at lysine 27 (designated as
H3K27me3) to silence chromatin regions268. PRC2 plays a key role in embryonic
development and maintenance of cell identity and may act as an oncogene or
tumor suppressor in different cellular contexts78. Cancer-associated perturbations
of PRC2 include both activating and loss-of-function mutations in EZH2, loss of
function mutations in H3K27 demethylase genes KDM6A/B, and H3K27M
mutations and dysregulation of the SWI/SNF chromatin remodeling complex,
which is a PRC2 antagonist77,78. Many studies have shown that high levels of EZH2

correlated with worse prognosis in cancer types including breast and lung
cancers82,83, and enforced EZH2 expression is oncogenic in the lung and drives
sensitivity to pharmacological inhibition of EZH281. However, several studies have
observed a de-coupling of EZH2 protein levels from H3K27me3 levels214,269-271,
and EZH2 is known to have non-catalytic functions115,272,273, underlining the
complex role EZH2 plays in tumorigenesis. Supporting a role of PRC2 as a tumor
suppressor in lung adenocarcinomas, deletion of the PRC2 component Eed
enhanced malignancy in KRAS+/Trp53-null lung cancers by driving aggressive
mucinous tumors and changing the tumor immune microenvironment100. Likewise,
deletion of Ezh2 in the context of oncogenic KRAS and intact Trp53 drove
aggressive lung cancers and exacerbated immune cell infiltration101. Collectively,
EZH2 plays divergent roles in different cellular contexts of cancer, which requires
comprehensive characterization.
Discovery of the contexts in which pharmacological inhibitors of epigenetic
enzymes, including EZH2, can be combined for the best anti-cancer outcomes is
an important challenge for the field. Recently tazemetostat (EPZ-6438), an inhibitor
of the catalytic activity of EZH2, was approved for treatment of advanced
epithelioid sarcoma, and numerous clinical and preclinical trials are focused on
combining EZH2 inhibitors with other drugs. One clear consequence of EZH2
inhibition is a dramatic shift in the immune cell microenvironment, which many are
hoping to further exploit274,275. In addition, a PRC2-low state that can be achieved
through EZH2 inhibition may sensitize tumor cells to additional epigenetic
therapies. For example, due to a switch from H3K27me3 to acetylation at the same
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residue, PRC2-deficient malignant peripheral nerve sheath tumors were found to
be sensitive to an inhibitor of H3K27ac-reader bromodomain and extra-terminal
motif (BET) proteins when combined with MEK inhibition276. Similarly, JQ1, the
BET inhibitor, showed combinatorial synergy with EZH2 inhibition in diffuse
intrinsic pontine glioma, which is already sensitive to EZH2 inhibitors due to altered
epigenetic state caused by H3K27M mutations104,277,278. Lastly, GSK-J4, which
inhibits histone demethylases and stabilizes H3K27me3, has been shown effective
at defeating chemo-resistant lung cancer cells and mammosphere-derived breast
cancer stem cells, both of which harbored decreased H3K27me3279-281. Therefore,
identifying proper contexts or combinatorial regimens is critical to realize the full
potential of epigenetic inhibitors for cancer therapy.
In addition to gene expression control through epigenetic mechanisms,
transcription factors are known to be master regulators of important cellular
phenotypes including stemness, proliferation, and migration282,283. Forkhead box
protein P2 (FOXP2) is a member of the FOX transcription factor family that all
share a conserved forkhead or “winged-helix” DNA binding domain284. In addition
to its role in the development of speech, FOXP2 is also known to be expressed in
developing embryonic lung and can be used to mark induced pluripotent stem cell
derived alveolar lung progenitors285,286. Knockout of Foxp2 led to severely
defective postnatal lung alveolarization in murine models287. In the adult, FOXP2
was found expressed in the distal lung epithelium, and can directly inhibit lung cell
differentiation genes including surfactant protein C and secretoglobin family 1A
member 1 transcription288,289. In cancers, FOXP2 activity has been identified as
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dysregulated

290

. While FOXP2 repression is correlated with poor outcome in

breast cancers, increased expression is associated with relapse in prostate cancer
and lymphoma291-294. Despite clues suggesting the importance of this transcription
factor in maintaining stemness in lung epithelium, the roles of FOXP2 in lung
adenocarcinoma have yet to be explored.
In this study, we demonstrate that Ezh2 haplo- and full-insufficiency lead to
divergent phenotypes in KRAS+/Trp53-null lung ADC by using genetically
engineered mouse models (GEMMs). Pharmacological inhibition of BET proteins
or H3K27 demethylases impeded tumor growth preferentially in PRC2-deficient
lung tumors in vitro and in vivo. Biochemical and transcriptional analysis revealed
PRC2 ablation-induced FOXP2 enrichment promotes lung tumor stemness and
migratory potency, partially phenocopying the effect of Ezh2 knockout in GEMMs.
Moreover, FOXP2 could be attenuated by BET inhibitor JQ1. Taken together,
FOXP2 expression governed by Polycomb activity dictates the tumor
aggressiveness and responsiveness to epigenetic therapies in lung cancer.

3.2

Ezh2 haplo- and full-Insufficiency drive distinct phenotypes in
KRAS+/Trp53-null lung cancer
To address the role of EZH2 in lung tumor initiation and progression, we

generated

the

LSL:KrasG12D/+;

Trp53flox/flox (LSL:

lox-stop-lox)

genetically

engineered mouse model with either zero, one, or two floxed alleles of Ezh2 and
induced autochthonous lung tumors by intranasal adeno-Cre (AdCre) virus
administration (Fig. 3.1a). We analyzed closely related mice of each Ezh2
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genotype at a variety of timepoints by histological examination of the resulting
KRAS+/Trp53-null lung tumors (Fig. 3.1b). Mice with one floxed allele of Ezh2
(Ezh2 heterozygous) had lower tumor burden (30%) when compared with Ezh2
wild-type mice (37%) between 82 and 130 days after AdCre delivery (Fig. 3.1c
and 3.1d). Ezh2 heterozygous mice also had tumors with lower nuclear grade and
showed increased survival (131.5-day median) when compared with Ezh2 wildtype mice (121.5-day median) (Fig. 3.2a and 3.2b). These results were consistent
with the role of EZH2 as an oncogene 81,100. However, mice with two floxed alleles
of Ezh2 (Ezh2 null) had significantly higher tumor burden (47%), significantly
higher nuclear grade, and a significantly shorter survival (114.5-day median) when
compared to Ezh2 heterozygous tumors. Strikingly, Ezh2 null tumors had a
significantly higher propensity to metastasize to areas including lymph nodes,
pleural space, chest wall, diaphragm, and liver than Ezh2 wild-type or
heterozygous tumors (Fig. 3.2c). Immunohistochemical staining revealed that
Ezh2 null tumor cells were nearly uniform in the lack of EZH2 expression and had
heterogenous but overall low staining for H3K27me3 (Fig. 3.2d and 3.2e). Rare
lung tumors and one lymph node metastasis were noted to retain EZH2 expression
in the Ezh2fl/fl mice, and EZH2 expression was heterogenous in Ezh2 wild-type and
heterozygous mouse tumors. H3K27me3 staining was uniformly moderate in both
Ezh2 wild-type and Ezh2 heterozygous tumors, appearing to be most prominent in
well differentiated Ezh2 heterozygous tumors. Notably, for Ezh2 null tumors,
despite heterogeneity among nodules, areas with larger pleomorphic nuclei had
low H3K27me3 staining. Due to the previous reports that loss of Eed in the
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KRAS+/Trp53-null model drove epithelial to mesenchymal transition (EMT) and
mucinous adenocarcinomas100, Alcian Blue and Masson’s Trichrome stains were
performed. Rare areas of intracellular Alcian Blue staining were observed in Ezh2
null tumors, and a few cases of goblet cell and squamous differentiation were
observed in Ezh2 heterozygous tumors, although the majority of the tumors in all
Ezh2 genotypes had no Alcian Blue stain (Fig. 3.2f). Consistent with a more
aggressive phenotype, some Ezh2 null tumors, especially the more poorly
differentiated tumors, had green collagen staining. Collectively, these data suggest
that full and partial insufficiency for Ezh2 drive distinct phenotypic outcomes in
KRAS+/Trp53-null lung adenocarcinomas with full insufficiency driving more
aggressive and metastatic tumors.
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Figure 3. 1 Ezh2 haplo- and full-Insufficiency drive distinct tumor burdens in
KRAS+/Trp53-null lung cancer
(a) Schematic for LoxP-mediated deletion of Ezh2 to generate EZH2 wild-type,
heterozygous,

and

homozygous

null

KRAS/Trp53-null

GEMMs.

(b)

Representative H&E stained cross sections from lungs of closely related mice that
were induced and sacrificed at the same timepoint show an Ezh2 null mouse that
has higher tumor burden than its matched Ezh2 WT or heterozygous cohort. (c)
Tumor burden as percentage of total lung was analyzed by ImageJ for indicated
mice at days 82-130 post tumor induction, n=34 Ezh2 WT, n=44 Ezh2
heterozygous and n=30 Ezh2 null, * indicates p=0.0287 Ezh2 WT vs Ezh2
heterozygous and ** indicates p=0.0032 Ezh2 WT vs Ezh2 null by ANOVA with
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pairwise comparisons. (d) Tumor burden relative to the whole lung indicated at the
different time points post Adeno-Cre, * at Day116-130 indicates p=0.027 Ezh2 WT
vs null, * at Day91-105 indicates p=0.026 Ezh2 heterozygous vs null, ** indicates
p<0.003 Ezh2 WT vs null by 2 tailed student’s T-test.
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Figure 3. 2 Ezh2 haplo- and full-Insufficiency drive distinct phenotypes in
KRAS+/Trp53-null lung cancer

(a) Overall survival of mice of indicated genotypes is graphed, n=10 Ezh2 WT,
n=18 Ezh2 heterozygous and n=18 Ezh2 null, * indicates p=0.022 Ezh2 WT vs
Ezh2 heterozygous, *** indicates p=0.0002 Ezh2 heterozygous vs Ezh2 null by
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Mantel-Cox log-rank test. (b) Nuclear grade was scored by a blinded pathologist
as done previously

242

on sections 108-120 post tumor induction, n=6 Ezh2 WT,

n=9 Ezh2 heterozygous and n=8 Ezh2 null, * indicates p<0.041 by ANOVA with
pairwise comparisons. (c) Mice of indicated genotypes were scored as having
metastasis or not by gross examination and histology at days 91-130 post tumor
induction, n=30 Ezh2 WT, n=36 Ezh2 heterozygous and n=25 Ezh2 null, *
indicates p=0.012 and *** indicates p=0.0008 by Fisher’s Exact test. (d)
Representative images of tumor sections with the indicated stains, scale
bar=100µm. (e) Box and Whisker plot of average percentage of positively stained
tumor nuclei for EZH2 in mouse lung tumors with the indicated Ezh2 genotypes,
*** indicates p<0.001 compared with Ezh2 null. (f) Representative images of Alcian
Blue and Masson’s Trichrome stains on the mouse tumor sections with the
indicated genotypes, scale bar = 100µm.
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3.3

Model systems differ in cell cycle and gene expression
Next, we sought to understand the major mechanisms behind the different

phenotypes among the three genotypes. To this end, we used four different cell
states to study: 2D cell lines, 3D tumor spheroids, freshly sorted tumor cells or
total (bulk) tumors. The sorted cells are almost pure epithelial tumor cells without
endothelial cells, lymphocytes and other blood cells from the microenvironmental
niche, which were retained in the total tumor samples. In general, 3D tumor
spheroids had cellular structures reminiscent of those found in tumors, including
pseudo stratification and apical-basal polarity of the epithelial cell layers (Fig.
3.3a). Consistent with previous reports100, 2D Ezh2 null cells exhibited more
elongated mesenchymal-like cells than 2D Ezh2 wild-type cells, whereas in crosssections of 3D tumor spheroids and in vivo tumors, the mesenchymal-like
phenotype was less obvious. We next queried Ezh2 mRNA expression patterns,
and found that in both 2D and 3D states, Ezh2 null cells expressed lower level of
Ezh2 than the other two genotypes (Fig. 3.3b). The expression of PRC2
associated proteins was verified in immunoblot, in which Ezh2 null cells showed
lower EZH2 and H3K27me3 levels compared with Ezh2 wild-type or heterozygous
lines (Fig. 3.3c). EED and SUZ12, the other two primary PRC2 components, were
also partially degraded in Ezh2 null cultures, presumably due to the complex
disassembly of PRC2-EZH2295,296. Interestingly, 2D cultures expressed more
EZH2 than 3D cultures by mRNA analysis, suggesting that 2D cell culture drives
an artificial increase in EZH2 expression.
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Because cellular proliferation is one of the key aspects of any culture
system, we next compared the cell cycle profiles of 2D cell lines and 3D tumor
spheroids. Cell cycle profiles of 2D cells and 3D spheroids were dramatically
different, with 2D cells showing much higher percentages of cells in S phase and
much lower percentages of cells in G0/G1 phase than 3D tumor spheroids for
every Ezh2 genotype (Fig. 3.4a and 3.4b), which coincides with the observations
that 2D cells propagate much faster than 3D spheroids. Intriguingly, mono-allelic
deletion of Ezh2 resulted in G2/M arrest in 2D cells, but led to G0/G1 arrest in 3D
tumor spheroids. In contrast, biallelic loss of Ezh2 did not trigger the arrest of 2D
cells in G2/M or 3D tumor spheroids in G0/G1, partially explaining opposing
phenotypes driven by Ezh2 heterozygous and homozygous deletion. However,
Ezh2 biallelic deletion in 3D tumor spheroids induced more S and G2/M phases
and less G0/G1 phase compared with mono-allelic deletion, demonstrating that
the cell cycle regulation is one mechanistic difference between these Ezh2
genotypes observed only in 3D cultures.
To understand the transcriptional differences that may contribute to the
disparity of phenotypes in the different systems, we compared mRNA from the
four models (independent of Ezh2 genotype) by RNA-sequencing. Unsupervised
hierarchical clustering of samples using distances derived from weighted
correlation showed that in vivo sorted tumors form their own cluster that is distinct
from all other samples, while total tumor is also distinct from the 3D tumor
spheroids and 2D cells, regardless of Ezh2 phenotype (Fig. 3.5a). Principal
Component (PC) analysis performed on all samples determined that PC3 showed
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a stratification of the 2D samples away from the other three groups (Fig. 3.5b).
This PC is enriched for genes associated with epithelial cell proliferation, lung
development, wound healing, cell-cell interactions and immune response (Table
3.1). Similarly, Gene Set Enrichment Analysis (GSEA) showed that compared with
2D cells, 3D tumor spheroids and in vivo sorted tumors had enrichment of
transcriptional signatures related to immunity and lung lineage determination (Fig.
3.5c and Table 3.2). In contrast, 2D cells were enriched for cell cycle gene
signatures, consistent with our findings in 2D cultures of increased S phase in the
cell cycle analyses. Notably, although some chromatin-related signatures showed
discordance of enrichment patterns, genes identified as changed by EZH2 and
EED knock-down in fibroblasts were similarly enriched in 3D tumor spheroids and
in vivo tumors when each was compared to 2D cultures297. Similarly, a recent
study using CRISPR-based screen showed that pathways associated with DNA
replication or other essential cellular functions were enriched in 2D human lung
cancer lines, while cancer-specific pathways, including RAS and p53 pathways,
were enriched in 3D spheroid culture226. Consistent with the cell cycle analysis,
Ezh2 heterozygous deletion resulted in significantly enriched hallmarks
associated with G2/M checkpoints and E2F targets only in 2D culture (Fig. 3.5d).
There was no such enrichment induced by Ezh2 full deletion in 2D culture, but it
led to reduced transcriptional enrichment in G2/M checkpoints and E2/F target
genes in sorted tumors compared to Ezh2 wild-type (data not shown). These data
demonstrate the substantial differences among culture systems in growth patterns
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and transcriptional states, and suggest adopting appropriate models for the study
of specific phenotypes.
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Figure 3. 3 Model systems differ in morphology and expression of PRC2
molecules

(a) Representative images of in vivo tumor histology, in vitro 3D tumor spheroid
histology and 2D cell cultures of the indicated Ezh2 genotypes, scale bar=100µm.
(b) Expression of Ezh2 mRNA in mouse primary 2D cells and 3D tumor spheroids
of the indicated Ezh2 genotypes determined by RT-qPCR, n=3 different cultures
for each genotype, * indicates p<0.043, ** indicates p<0.009. (c) 2D and 3D cells
were examined for expression of the indicated proteins by immunoblot. H3
indicates total histone H3 and is the loading control.
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b

Figure 3. 4 Model systems differ in cell cycle

(a) Percentages of cells in each cell cycle phase were measured by 7AAD cell
cycle flow cytometry 2D cells and 3D tumor spheroids of the indicated Ezh2
genotypes, n=4 Ezh2 WT, n=3 Ezh2 heterozygous and n=4 Ezh2 null for 2D and
n=3 Ezh2 WT, n=4 Ezh2 heterozygous and n=3 Ezh2 null for 3D, * indicates
p<0.039, ** indicates p<0.009, *** indicates p<0.001. (b) Cell cycle profiles of 2D
vs 3D cells within the indicated genotypes, * indicates p<0.039, ** indicates
p<0.009, *** indicates p<0.001.
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Figure 3. 5 Model systems differ in gene expression

(a) Heatmap of sample-to-sample correlations using highest loading genes from
PC3, where the Pearson correlations are weighted by sample-sample information
and sample-sample consistency (see Methods). The 1 - correlation value was then
used as a pseudo distance for hierarchical clustering and ordered using default
argument of dendsort, n=17 for total tumor, n=13 for sorted tumor, n=20 for 2D
cells and n=21 for 3D spheroids. (b) Principal component analysis of the variability
of gene expressions in the indicated model systems. Sample scores from PC1 and
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PC2 (left graph) and PC1 and PC3 (right graph) of a principal component
decomposition of the log(TPM + 1) values for each sample are shown. (c) Rank
ordered gene lists were queried against the MSigDB databases and enrichment
scores of selected gene signatures enriched in 2D, 3D, or in vivo sorted tumors
were plotted. Size of dots estimates false discovery rate (FDR). (d) GSEA plots
evaluating the changes in the indicated gene signatures in 2D Ezh2 heterozygous
compared with 2D Ezh2 wild-type mouse cells.
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Table 3. 1 Gene Enrichment for Principle Component 3 on All Models (Top 40)

GO Term

Description

Enrichment.
p

Enrichment.
odds

Enrichment.
expected

Enrichment.
counts

Enrichment.
p.adjust

GO:0031012

extracellular matrix

1.60E-14

2.703872

41.16202

94

5.87E-12

GO:0045177

apical part of cell

7.09E-14

2.780568

36.31424

85

2.31E-11

GO:0062023

collagen-containing extracellular matrix

1.81E-13

2.916182

31.20204

76

5.73E-11

GO:0009611

response to wounding

4.18E-12

2.523357

39.66362

86

1.13E-09

GO:0048871

multicellular organismal homeostasis

6.13E-12

2.457509

41.95529

89

1.60E-09

GO:0009615

response to virus

1.19E-11

3.080934

23.09304
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3.02E-09

GO:0030198

extracellular matrix organization

1.22E-11

3.044034

23.71003

60

3.05E-09

GO:0043062

extracellular structure organization

1.44E-11

3.029359

23.79817

60

3.48E-09

GO:0016324

apical plasma membrane

1.92E-11

2.825989

27.67639

66

4.54E-09

GO:0050900

leukocyte migration

4.28E-11

2.715119

29.43922

68

9.71E-09

GO:0050673

epithelial cell proliferation

4.95E-11

2.489046

36.75495

79

1.10E-08

GO:0030595

leukocyte chemotaxis

1.03E-10

3.275724

18.24526

49

2.11E-08

GO:0051607

defense response to virus

1.63E-10

3.133232

19.65552
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3.28E-08

GO:0060326

cell chemotaxis

2.30E-10

2.787231

25.38471

60

4.45E-08

GO:0050839

cell adhesion molecule binding

2.40E-10

3.012289

21.06579

53

4.58E-08

GO:0030546

signaling receptor activator activity

2.61E-10

2.304516

42.13157

85

4.93E-08

GO:0048018

receptor ligand activity

3.20E-10

2.305973

41.60273

84

5.99E-08

GO:0042060

wound healing

4.67E-10

2.54032

31.02576

68

8.53E-08

GO:0031589

cell-substrate adhesion

5.28E-10

2.572974

29.79178

66

9.49E-08

GO:0042379

chemokine receptor binding

6.14E-10

6.770754

4.935917

22

1.10E-07

GO:0001667

ameboidal-type cell migration

6.99E-10

2.403898

35.34469
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1.24E-07

GO:0016323

basolateral plasma membrane

8.40E-10

2.999406

19.91995

50

1.47E-07

GO:0043588

skin development

2.12E-09

2.678616

24.85587

57

3.55E-07

GO:0046977

TAP binding

2.90E-09

93.61202

0.881414

9

4.83E-07

GO:0050678

regulation of epithelial cell proliferation

7.41E-09

2.397907

31.02576
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1.20E-06

GO:0005902

microvillus

7.71E-09

4.49066

7.932723

27

1.24E-06

GO:0050878

regulation of body fluid levels

8.68E-09

2.424222

29.79178
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1.38E-06

GO:0090132

epithelium migration

8.95E-09

2.60486

24.5033

55

1.40E-06

GO:0090130

tissue migration

1.16E-08

2.581401

24.67958

55

1.77E-06

GO:0048525

negative regulation of viral process

1.74E-08

4.132851

8.725995

28

2.53E-06

GO:0010631

epithelial cell migration

1.82E-08

2.567568

24.32702

54

2.63E-06

GO:1990868

response to chemokine

2.20E-08

5.228886

5.81733

22

3.07E-06

GO:1990869

cellular response to chemokine

2.20E-08

5.228886

5.81733

22

3.07E-06

GO:0045785

positive regulation of cell adhesion

2.18E-08

2.2257

36.04982

71

3.07E-06

GO:0019221

cytokine-mediated signaling pathway

2.59E-08

2.379486

29.26293

61

3.57E-06

GO:0005903

brush border
regulation of interspecies interactions
between organisms
extracellular matrix structural
constituent

2.75E-08

3.498254

11.63466

33

3.75E-06

3.06E-08

2.926389

17.01128

42

4.08E-06

3.07E-08

3.399201

12.25165

34

4.08E-06

epithelial cell development
negative regulation of viral genome
replication

3.17E-08

2.690378

20.80136

48

4.19E-06

3.57E-08

5.648252

5.024058

20

4.66E-06

GO:0043903
GO:0005201
GO:0002064
GO:0045071
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Table 3. 2 Gene Set Enrichment Analysis Model Compare
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3.4

Ezh2 deficiency leads to diverse gene expression in different models
In order to understand the molecular consequences of Ezh2 complete

deletion in vitro and in vivo, we next used the RNA-sequencing data to investigate
the transcriptional results between Ezh2 null and Ezh2 wild-type in each model
system. When comparing Ezh2 null with Ezh2 wild-type genotypes, we dropped
the total tumor samples, because they were extremely heterogeneous,
presumably due to the interference of blood cells and endothelial cells, and did not
produce many significantly differentially expressed genes among the Ezh2
genotypes (Fig. 3.6a). Sorted tumors had the fewest significantly differentially
expressed genes while 3D tumor spheroids had the most significantly differentially
expressed genes (Fig. 3.6b, LFC>0.5 and LFC<0.5, FDR<0.05). Only one gene,
Ezh2, was shared as differentially expressed for all three systems. In 2D cultures,
a large cluster of Hox genes was significantly upregulated in Ezh2 null cells
compared to Ezh2 wild-type cells. However, there was no upregulation of Hox
genes in 3D and sorted tumors, which indicated that Hox gene de-repression may
be an effect specific to propagating Ezh2 null cells in 2D systems. In 3D tumor
spheroids, genes relating to lung cell differentiation such as Spdef, Muc5ac,
Lamp3, and Trp63 were differentially regulated in Ezh2 null cells, whereas these
same lung lineage genes were too lowly expressed to detect in 2D cell lines.
Eleven genes were found to be differentially expressed shared by 3D and sorted
comparisons. Of these genes, Forkhead Box Protein 2 (Foxp2), encodes for a
transcription factor vital in embryonic lung development, and was significantly
higher in Ezh2 null 3D tumor spheroids and in vivo sorted tumors than in Ezh2
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wild-type counterparts (LFC=5.5, FDR=0.00009 and LFC=1.01, FDR=0.0003
respectively). Intriguingly, in 2D cultures Foxp2 was not detected in any Ezh2
genotype by our RNA-sequencing methods.
GSEA comparing Ezh2 null to Ezh2 wild-type cells from the different
systems showed the level of complexity of PRC2-mediated gene regulation in the
different systems (Fig. 3.7a and Table 3.3). The only signature identified to be
upregulated in Ezh2 null cells in all systems including total tumors was that of
imprinted genes, supporting our previous observations that imprinted gene
expression is controlled through Polycomb complexes298. Gene signatures of
immune responses were enriched in Ezh2 wild-type 3D, sorted and total tumors
cells, but often enriched in Ezh2 null 2D cells. Similarly, only in 2D cultures did
Ezh2 null cells show the dramatic up-regulation of the Polycomb target gene
signatures, and it is notable that many of these signatures were defined in 2D
systems. As shown previously, HOX gene signatures were unique to Ezh2 null 2D
cells. Signatures unique to Ezh2 null cells in 3D systems appeared to center
around lipid and steroid catabolism, whereas in sorted tumor cells, Ezh2 null cells
had enrichment for growth factor signaling, in line with the vast differences
between model systems commonly used for cancer research. Collagen and EMT
signatures were enriched in Ezh2 null cells only in 2D and total tumors, consistent
with previous study in Eed knockout mouse100, but not in 3D and sorted tumors,
suggesting that while there is a mesenchymal component to Ezh2 null tumors, the
extent of EMT is context specific. In addition, in vivo Ezh2 heterozygous tumors
also had significantly less enrichment for immune cell signatures than Ezh2 WT
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and null tumors (Fig. 3.7b and Table 3.4). Furthermore, Ezh2 heterozygous tumor
cells in vivo had enrichment for histone methylation gene signatures, suggesting a
feed-back mechanism triggered by haplo-insufficiency for Ezh2 that leads to more
robust chromatin regulation.
To accurately assess the changes of immune microenvironment in each
genotype, RNA-sequencing results of total tumors were used to calculate the
infiltrations of various immune cells by TIMER2.0299-301. Interestingly, Ezh2
heterozygous tumors carried significantly more tumor-infiltrating CD8+ T cells,
monocytes and fewer cancer associated fibroblasts, indicating an anti-tumor
immune microenvironment of the Ezh2 heterozygous tumors (Fig. 3.7c). In
contrast, Ezh2 full deletion resulted in fewer naïve B cells, M1 macrophages and
resting CD4+ memory T cells, and more activated CD4+ memory T cells. When
focusing on the cell autonomous effects, gene sets related to diverse epithelial cell
differentiation, embryonic morphogenesis or organ formation, were extensively
less enriched in 3D and sorted Ezh2 null tumors compared to Ezh2 wild-type (data
not shown). Ezh2 null sorted tumors were also less enriched in lung cell
differentiation signature compared to Ezh2 heterozygous sorted tumors,
suggesting that Ezh2 full deletion brings lung cancer cells to a more poorly
differentiated state (Fig. 3.7d). It is consistent with the observations that Ezh2 null
tumors have higher average nuclear grades than the other two genotypes (Fig.
3.2b). Together, these data show that Ezh2 deprivation drives diverse
transcriptional changes associated with immune microenvironment and cell
autonomous effects.
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a

b

Figure 3. 6 Ezh2 deficiency leads to diverse gene expression in different models

(a) Distributions of differentially expressed genes Ezh2 null vs WT are shown as
volcano plots in the indicated model systems. FDR cut-off is 0.05 and log2 fold
change cut-off is 1. (b) Venn Diagram and heatmaps depicting significantly
differentially expressed genes in Ezh2 null vs. WT cells in the indicated culture
systems, with log-fold change (LFC)>1 and LFC<-1, FDR<0.05. Genes higher in
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Ezh2 null are in red, genes lower in Ezh2 null are in blue. Heatmaps depict LFC of
selected genes identified by the indicated contrasts.
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d

b

c

Figure 3. 7 Ezh2 deficiency leads to diverse enriched gene signatures in different
models
(a) Rank ordered gene lists were queried against the MSigDB databases and
enrichment scores of selected gene signatures enriched in Ezh2 null or Ezh2 WT
samples in 2D, 3D, in vivo sorted and total tumors were plotted. Size of dots
estimates false discovery rate (FDR). (b) Rank ordered gene lists were queried
against the MSigDB databases and enrichment scores of selected gene signatures
enriched in Ezh2 heterozygous vs null samples in the indicated model systems
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were plotted. Size of dots estimates false discovery rate (FDR). (c) Infiltrations of
the indicated immune cell types were estimated by TIMER2.0 analysis in the
samples with indicated genotypes, * indicates p<0.038, ** indicates p=0.00613 and
*** indicates p<0.00038. (d) GSEA plots evaluating the changes in the indicated
gene signatures in sorted Ezh2 null compared with sorted Ezh2 heterozygous
mouse cells.
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Table 3. 3 Gene Set Enrichment Analysis Ezh2 Null vs Ezh2 WT
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Table 3. 4 Gene Set Enrichment Analysis Ezh2 Het vs Ezh2 WT or Ezh2 Null
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3.5

Loss of PRC2 activity drives increased FOXP2 expression in normal and
malignant lung cells
We next sought to understand if Foxp2 was a direct PRC2 target gene. First,

we confirmed the expression of FOXP2 in 2D and 3D cells at the mRNA and
protein levels. Foxp2 was significantly elevated in Ezh2 null cells in both 3D tumor
spheroids and 2D cultures (Fig. 3.8a and 3.8b). The reason why Foxp2 was not
detected as significantly changed in 2D cultures by RNA-sequencing is that its
expression is too low to generate sufficient reads by standard RNA-sequencing
parameters. In contrast, Foxp2 mRNA levels were significantly higher (>30-fold) in
Ezh2 null 3D tumor spheroids than in Ezh2 null 2D cells. Furthermore, single cell
RNA-sequencing showed that Foxp2 was significantly elevated in normal murine
lung organoids in which Ezh2 was knocked-out, implying that PRC2 governs
Foxp2 not only in malignant but also in normal lung epithelial cells (Fig. 3.8c).
Then, to test if EZH2 inhibition leads to de-repression of FOXP2 in human
samples, we measured FOXP2 mRNA of human cell lines treated with EPZ-6438.
In line with the discovery in murine cells, inhibition of EZH2 elevated FOXP2
expression in human cancer lines H460, H2030, A549 and H2009, or transformed
pulmonary epithelial cells HBEC3KT, BEAS2B and BEAS-KP (Fig. 3.9).
To interrogate whether EZH2/PRC2 directly regulates Foxp2, we performed
chromatin immunoprecipitation (ChIP) followed by quantitative PCR (qPCR) on
mouse Ezh2 wild-type and Ezh2 null 3D spheroids. In the murine system, there
was a trend of decreased H3K27me3 occupancy at the protein initiation site (ATG)
and enhancer region of Foxp2 in Ezh2 null cells compared with Ezh2 wild-type
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cells (Fig. 3.10a). Furthermore, H3K27ac, a marker of active chromatin, was
enriched at the transcription start site (TSS) and enhancer region of Foxp2 in the
Ezh2 null spheroids. Similarly, in BEAS-KP cells, an immortalized human bronchial
epithelial cell line BEAS2B with additional KRASG12V and TP53R175H mutations,
treatment of EPZ-6438/tazemetostat, the FDA-approved EZH2 inhibitor, caused a
significant loss of H3K27me3 enrichment at the TSS and enhancer regions of
FOXP2 (Fig. 3.10b). Correspondingly, H3K27ac was enriched at the TSS and
enhancer regions of FOXP2 in BEAS-KP with EZH2 inhibition. Intriguingly, in Ezh2
null and EZH2 inhibited cells, FOXP2 was more enriched at the TSS and enhancer
regions of FOXP2, indicating that this transcription factor may self-regulate. In
summary, these data show that FOXP2 is a direct target of the PRC2 complex and
that loss or inhibition of EZH2 increases FOXP2 expression in normal and
malignant lung cells of both mouse and human origin.
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Figure 3. 8 Loss of PRC2 activity drives increased FOXP2 expression in murine
lung cancer cells

(a) Relative expression of Foxp2 mRNA in mouse primary 2D tumor cells and 3D
tumor spheroids with the indicated Ezh2 genotypes determined by RT-qPCR, n=3
biological replicates for each genotype, * indicates p<0.038. (b) FOXP2 protein
expression in 2D cells and 3D spheroids of the indicated Ezh2 genotypes was
examined by immunoblot. H3 is total histone H3 and serves as the loading control.
(c) UMAP plots depict relative expression of Foxp2 mRNA in murine normal
organoids of the indicated Ezh2 genotypes.
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Figure 3. 9 Loss of PRC2 activity drives increased FOXP2 expression in human
normal and malignant lung cells

Expression of FOXP2 mRNA in human lines HBEC3KT, BEAS2B, BEAS-KP,
H460, H2030, A549, and H2009 with or without EPZ-6438 treatment for 10 days,
n=3 independent experiments per cell line, * indicates p<0.043, ** indicates
p<0.009, *** indicates p=0.0003.
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Figure 3. 10 Loss of PRC2 activity drives increased H3K27ac and decreased
H3K27me3 at genomic regions of FOXP2 expression

ChIP-qPCR on (a) 3D murine tumor spheroids with indicated genotypes and (b)
BEAS-KP treated with or without EPZ-6438 for 10 days for Foxp2 transcription
start site (TSS), translation start site (ATG) and enhancer region using antibodies
against H3K27me3 and H3K27ac, n=3 biological or technical replicates, * indicates
p<0.036, *** indicates p=0.00065.
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3.6

FOXP2 dictates stemness and migratory capacity of lung epithelial cells
Having established FOXP2 as a direct target of PRC2 in lung epithelial cells,

we next sought to understand if FOXP2 was driving the phenotypic differences
observed in Ezh2 null tumor cells. To this end, we overexpressed FOXP2 in normal
or malignant lung cells, and confirmed increased expression by immunoblot (Fig.
3.11a). When grown in Matrigel cultures, FOXP2 overexpressing BEAS2B cells
yielded more and significantly larger organoids than the control cells (Fig. 3.11bd). However, the same cells failed to grow in soft-agar experiments, suggesting
that FOXP2 promoted the stemness of BEAS2B cells without driving oncogenic
transformation (3.11b). Given the increased metastatic potential of Ezh2 null tumor
cells, we tested if FOXP2 overexpression changed migratory capability by
transwell migration assays. First, we confirmed that Ezh2 null mouse tumor cells
migrated significantly more than Ezh2 WT cells (Fig. 3.12a and 3.12b). Then, in
human lines HBEC3KT, BEAS2B, H460 and H2030, overexpression of FOXP2
also produced the cell lines with significantly increased migratory capacity when
compared to control cell lines (Fig. 3.12c and 3.12d). In line with this observation,
BEAS-KP with overexpressed FOXP2 grown in Matrigel formed more extensive
branching structures than control (data not shown). Furthermore, FOXP2
overexpression also conferred BEAS2B cells resistance to carboplatin and
etoposide (Fig. 3.13), consistent with the knowledge that cells in more stem-like
states are relatively resistant to chemotherapy302. To discover the transcriptional
programs changed by FOXP2 over-expression, we performed RNA-sequencing
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on FOXP2-overexpressing and control cell lines. GSEA revealed that FOXP2
overexpression drove transcriptional amplification of many genes associated with
EMT, cell adhesion, TNFα, RAS signaling, and lung development (Fig. 3.14a and
Table 3.5), partially overlapping with the altered pathways in 2D mouse cells with
Ezh2 full deletion. The finding of RAS signaling enrichment was not unique to the
H460 and H2030 KRAS mutated lines, but also happened in the HBEC3KT and
BEAS2B KRAS WT lines. Lastly, to link FOXP2 overexpression in human cell lines
to gene expression changes seen in Ezh2 null spheroids, we examined NDRG4
and MYCN in FOXP2 overexpressing or EZH2 inhibited H460 and H2030 3D tumor
spheroid cultures (Fig. 3.14b). These two genes were highly up-regulated in Ezh2
null spheroids, and are potential PRC2/FOXP2 downstream genes based on the
ENCODE data303. In these cultures, the combination of FOXP2 overexpression
and EZH2 inhibition led to the largest increases in NDRG4 and MYCN, confirming
that these genes are likely regulated by both PRC2 and FOXP2.
These data on FOXP2 over-expressed cells prompted us to test whether
FOXP2 inhibition could depress the aggressiveness of lung cancer. Knocking
down of FOXP2 with two different hairpins in the human H460 cell line remarkedly
impeded cell growth in 2D cultures (Fig. 3.15a-c). FOXP2 knockdown also led to
fewer and significantly smaller 3D spheroids formed compared with the control
shGFP (Fig. 3.15d and 3.15e), suggesting that targeting of FOXP2 could be a
potential therapeutic avenue in lung cancer. Moreover, the H460 cells with FOXP2
knockdown migrated significantly less than the control, indicating the
indispensability of FOXP2 in cell migration (Fig. 3.15f and 3.15g). Altogether,
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these discoveries identify the pivotal role of FOXP2 in stemness and migration of
lung epithelial cells, which are regulated in part through the downstream
transcriptional programs of PRC2/FOXP2 axis.
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Figure 3. 11 FOXP2 dictates stemness of lung epithelial cells

(a) FOXP2 protein expression in HBEC3KT, BEAS2B, H460, and H2030 cells
transduced with FOXP2 lentivirus was examined by immunoblot. EV is the empty
vector control line. H3 is total histone H3 and serves as the loading control. (b)
Representative images of 3D Matrigel and soft agar cultures seeded with BEAS2B
cells with or without FOXP2 overexpression, scale bar = 1000µm for Matrigel
cultures and 100µm for soft-agar cultures. (c) Average diameters and (d) count
numbers of BEAS2B 3D organoids with or without FOXP2 overexpression, n=3
independent experiments, * indicates p=0.034.
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Figure 3. 12 FOXP2 dictates migratory capacity of lung epithelial cells

(c) Representative images and (b) average numbers of migrated cells in Ezh2 wildtype UK803 and Ezh2 null UK777 mouse lines, n=4 technical replicates, **
indicates p=0.00167. (c) Representative images and (d) average numbers of
migrated cells in HBEC3KT, BEAS2B, H460, and H2030 cells with or without
FOXP2 overexpression, * indicates p<0.049, ** indicates p=0.004.
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Figure 3. 13 FOXP2 overexpression confers resistance to chemotherapy

Normalized dose-response to carboplatin and etoposide of BEAS2B cells with or
without FOXP2 overexpression, *** indicates p<0.0001 comparing models by extra
sum-of-squares F statistic.
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Figure 3. 14 FOXP2 overexpression cooperates with PRC2 to regulate gene
expression

(a) Rank ordered gene lists were queried against the MSigDB databases and
enrichment scores of selected gene signatures enriched in FOXP2 overexpressing cell lines relative to EV lines were plotted. Size of dots estimates FDR.
(b) Normalized mRNA expression of FOXP2, NDRG4, and MYCN with or without
FOXP2 overexpression with or without EPZ-6438 treatment on H460 and 2030 3D
samples.
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Figure 3. 15 FOXP2 knockdown suppresses cell proliferation, organoid formation
and migration of lung cancer
(a) FOXP2 protein expression in H460 cells transduced with indicated small
hairpins was examined by immunoblot. shGFP is the control cell line. H3 is total
histone H3 and serves as the loading control. (b) Crystal violet growth assays were
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performed on 2D H460 cells with or without FOXP2 knockdown at indicated days
of culture, n=6 independent experiments, ** indicates p<0.0024, *** indicates
p<0.001. (c) Representative whole well images of crystal violet stained H460 cells
with indicated small hairpins 6 days after seeding. (d) Average diameters and (e)
counts of 3D H460 spheroids with or without FOXP2 knockdown, n=6 independent
experiments, ** indicates p=0.007, *** indicates p<0.001 compared to shGFP
spheroids. (f) Average percentages normalized to shGFP and (g) representative
images of migrated cells in H460 with or without FOXP2 knockdown, n=4 technical
replicates, *** indicates p<0.001 by two-tailed Student’s T-test compared to shGFP
cells.
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Table 3. 5 Gene Set Enrichment Analysis of FOXP2 oe vs Empty Vector
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3.7

Polycomb deficiency drives BET and histone de-methylase inhibitor
sensitivity
We next aimed to identify epigenetic therapeutic vulnerabilities of PRC2-

deficient KRAS+/Trp53-null lung adenocarcinomas. We reasoned that because
Ezh2 null tumors were most aggressive, methods to stabilize PRC2 marks or
prevent reading of H3K27ac marks could allow for ‘re-normalization’ of the
aberrant epigenetic state. Therefore, we focused our efforts on testing the histone
demethylase inhibitor GSK-J4 and BET inhibitor JQ1 (Fig. 3.16a). Diverse culture
models were used to detect the sensitivities of these epigenetic inhibitors, including
in vitro systems of 2D standard cell culture, 3D Matrigel air-liquid interface
transwell culture, and in vivo nude mouse allografts and genetically modified
mouse model autochthonic tumors. In 2D monolayer cell culture, there were no
differences in half maximal inhibitory (IC50) values among the Ezh2 wild-type,
heterozygous, and null tumor cells treated with GSK-J4 or JQ1 (Fig. 3.16b).
However, when propagated in 3D air-liquid interface Matrigel cultures, Ezh2 null
spheroids were more susceptible to GSK-J4 and JQ1 when compared with Ezh2
wild-type spheroids (Fig. 3.16c and 3.16d). Ezh2 heterozygous spheroids were
similarly sensitive to JQ1 as Ezh2 null, but only modestly sensitive to GSK-J4. The
lack of consensus between 2D and 3D cultures prompted us to investigate drug
vulnerabilities in vivo. 3D tumor spheroids were isolated and grafted
subcutaneously onto immunocompromised mice. Intriguingly, consistent with the
3D culture system, Ezh2 null allografts were growth-inhibited more strongly than
Ezh2 wild-type after GSK-J4 and JQ1 treatment in nude mouse, while the
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therapeutic effect of JQ1 on Ezh2 heterozygous allografts was between the former
two genotypes (Fig. 3.17a and 3.17b).
To test if JQ1 could decrease tumors growing in the native lung
microenvironment, we treated autochthonous tumor bearing mice with JQ1 and
measured changes in tumor volume by magnetic resonance imaging (MRI). Seven
days of JQ1 treatment reduced the volumes of the lung tumor nodules in Ezh2 null
GEMMs, while tumors continued to grow in the placebo group (Fig. 3.17c and
3.17d). An additional seven days of JQ1 administration was sufficient to retain
tumors in their regressed state, though no additional tumor burden reduction was
observed. One mouse harboring Ezh2 heterozygous tumors also showed tumor
reduction with JQ1, mirroring results observed in 3D and allograft (data not shown).
To further explore the clinical significance of the drug vulnerability discoveries from
murine tumors, we used several KRAS mutated human non-small cell lung cancer
lines. Drug synergy matrix experiments demonstrated abundant synergy or
potently additive effect when combining JQ1 with EPZ-6438 in H2030, H2009, and
also BEAS-KP (Fig. 3.18a). Additionally, knocking down of EZH2 sensitized the
human line H2030 to JQ1 (Fig. 3.18b and 3.18c), and such sensitization was more
observable in 3D spheroid culture than 2D culture in H460 (Fig. 3.18d).
The differential response to BET inhibitor inspired us to interrogate whether
FOXP2 was involved in its therapeutic effect in EZH2-deficient cells. First, we
performed RNA-sequencing on the 3D tumor spheroids and allografts treated with
JQ1, which revealed that BET inhibition led to decreased Foxp2 expression
primarily in Ezh2-insufficient cells (Fig. 3.18e). c-Myc, one of the more common
88

genes changed by JQ1

304

, was also decreased in expression in the allograft,

which confirms efficacy of the drug. Genes upregulated by FOXP2, including the
PRC2/FOXP2 downstream genes Mycn and Ndrg4, and genes associated with
lung differentiation, such as keratin genes, Sftpb and Scgb3a2, were also
repressed by JQ1 in the Ezh2 null allograft setting. RT-qPCR on mouse 3D tumor
spheroids also showed that 25nM JQ1 increased Foxp2 expression in Ezh2 wildtype but slightly reduced it in Ezh2 heterozygous and null spheroids (Fig. 3.18f).
Foxp2 was significantly inhibited by 100nM JQ1 in Ezh2 heterozygous and null
tumor spheroids, but not in Ezh2 WT tumor spheroids, which may explain the
difference in drug sensitivity among the genotypes. Similarly, in the H2030 cell line,
knock-down of EZH2 which we previously showed conferred sensitivity to JQ1, led
to increased FOXP2 expression (Fig. 3.18g). Treatment of these lines with JQ1
showed that FOXP2 levels were significantly decreased in the shEZH2 lines, but
not in the shGFP line, again suggesting that regulation of FOXP2 correlated to the
increased sensitivity of cells to JQ1. Taken together, these data indicate that EZH2
blockade confers sensitivity to BET inhibition and demethylase inhibition in lung
adenocarcinoma, and FOXP2 could be a promising target of BET inhibitor.
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Figure 3. 16 Polycomb deficiency drives BET and histone de-methylase inhibitor
sensitivity in murine 3D culture in vitro

(a) Schematic depicting the mechanisms to restore epigenetic states lost in PRC2deficient tumors. (b and c) GSK-J4 and JQ1 dose-response curves of (b) 2D
primary cells from different donor mice, n=5 Ezh2 WT, n=6 Ezh2 heterozygous and
n=6 Ezh2 null; and (c) 3D spheroids, n=7 Ezh2 WT, n=5 Ezh2 heterozygous and
n=5 Ezh2 null, *** indicates p=0.0004, ** p=0.0023 for Ezh2 WT vs Ezh2 null. (d)
Images of placebo-, GSK-J4- and JQ1-treated spheroids of the indicated Ezh2
genotypes. (b) Wet weights of placebo-, GSK-J4- and JQ1-treated in vivo allografts
of the indicated Ezh2 genotypes.
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Figure 3. 17 Polycomb deficiency drives BET inhibitor sensitivity in murine
tumors in vivo

(a) Changes in volumes of allografts in mice treated with GSK-J4 and JQ1 relative
to changes in volumes of allografts in placebo treated mice are plotted over time.
Donor mice for GSK-J4 experiments were n=5 Ezh2 WT, n=5 Ezh2 heterozygous
and n=4 Ezh2 null; donor mice for JQ1 experiments were n=5 Ezh2 WT, n=5 Ezh2
heterozygous and n=6 Ezh2 null, *** indicates p<0.001 and * indicates p<0.0486
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compared with Ezh2 WT repeated measures ANOVA. (b) Wet weights of placebo, GSK-J4- and JQ1-treated in vivo allografts of the indicated Ezh2 genotypes. (c)
Quantification of relative tumor volume change after 1 week and 2 weeks of
placebo or JQ1 treatment of Ezh2 null tumor bearing mice, ** indicates p<0.005
repeated measures ANOVA. (d) Representative magnetic resonance images of
mouse lungs at baseline (week 0) and week 1 of JQ1 treatment.
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Figure 3. 18 EZH2 inhibition synergizes with BET inhibition in mouse and human
cancers
(a) Heatmap of Bliss synergy scores of EPZ-6438 combined with JQ1 in H2030,
BEAS-KP and H2009 cultures. 3 or 4 independent experiments were used to
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produce an average matrix. Overall Bliss synergy scores were 6.78, 5.84, and
6.47, respectively. Most synergist area Bliss scores were 8.56 for H2030, 10.57
for BEAS-KP, and 10.05 for H2009. (b) H2030 and H460 2D cells with or without
EZH2 knock-down were examined for the expression of the indicated proteins by
immunoblot. H3 indicates total histone H3 and is the loading control. (c)
Normalized dose-response to JQ1 of H2030 cells with or without EZH2 knockdown, *** indicates p<0.0003 comparing models by extra sum-of-squares F
statistic. (d) Relative cell survival of H460 cells with or without EZH2 knock-down
in 3D (n=3) and 2D (n=4) cultures to JQ1 treatment compared with vehicle control.
(e) Heatmap depicting log-fold change (LFC) in gene expression after JQ1
treatment in the indicated genotypes relative to control, n=1 matched pair of JQ1
treated and vehicle treated for each column. (f) Expression of Foxp2 mRNA in
mouse 3D tumor spheroids treated with JQ1 25nM and 100nM for 7 days
normalized to expression in the vehicle control treated culture for the indicated
Ezh2 genotypes, * indicates p=0.012, ** indicates p=0.001. (g) Expression of
FOXP2 mRNA on H460 with or without EZH2 knockdown treated with vehicle or
100nM JQ1, * indicates p=0.022, ** indicates p=0.001.
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3.8

High EZH2 correlates with low H3K27me3 and high FOXP2 and predicts
advanced lung cancer
To extend our finding to human lung cancer patient samples, we performed

immuno-histochemical staining for EZH2, H3K27me3, and FOXP2 on lung cancer
tissues from 233 patients, including 92 adenocarcinoma (ADC) cases, 104
squamous cell carcinoma (SCC) cases, 24 adenosquamous (ADSCC) cases and
13 cases of poorly differentiated tumors including 1 sarcomatoid tumor. Consistent
with previous research214,269, the H3K27me3 stain was respectively higher in ADC
than SCC, while EZH2 had the opposite pattern of being higher in SCC and lower
in ADC (Fig. 3.19a). FOXP2 expression was variable in ADC samples, but often
found to be high in poorly differentiated tumors. Focusing on only ADC and poorly
differentiated lung tumors, we observed that well differentiated tumors often had
high H3K27me3, low EZH2 and low FOXP2 expression, while poorly differentiated
tumors had lower H3K27me3, higher EZH2 and sometimes had higher FOXP2
expression (Fig. 3.19b). Consistent with these staining patterns, in all ADC and
poorly differentiated samples, EZH2 expression was slightly inversely correlated
to H3K27me3 expression and was strongly positively correlated to FOXP2
expression (Fig. 3.19c). We next binned samples into groups that had high
expression or low/negative expression of EZH2 and H3K27me3 and found a
significant enrichment of EZH2 high and H3K27me3 low patterns in poorly
differentiated tumors compared to well differentiated tumors (Fig. 3.19d).
Similarly, by assessing the percentage of positive nuclei, poorly differentiated
ADCs had the higher EZH2 and lower H3K27me3 expression compared with well
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or moderately differentiated tumors. FOXP2 staining patterns showed that well
differentiated tumors could express FOXP2, but that FOXP2 expression was also
higher in poorly differentiated tumors than in moderately differentiated tumors.
EZH2 and H3K27me3 decoupling could be driven by multiple factors, and one
likely factor is that in highly proliferative tumors, although EZH2 may be increased,
availability of the methyl donor, S-adenosyl methionine (SAM), may be more
scarce100. To examine this hypothesis of SAM levels influencing PRC2 stability
and activity, 500μM SAM was added to the culture media of human lines H460,
A549 and BEAS-KP for 6 days. As expected, the cell lines treated with SAM all
showed higher H3K27me3, and meanwhile had lower EZH2 and FOXP2
compared to the control (Fig. 3.20a-c). Treating Ezh2 wild-type mouse line UK803
with SAM led to a similar decoupling of EZH2 and the H3K27me3 mark (Fig.
3.20d). These data suggest that when SAM is abundant, which may be the case
in slowly growing more well differentiated tumors, PRC2 activity is high and EZH2
is down-regulated. In more quickly proliferating tumors, EZH2 is upregulated but
a lack of SAM leads to an overall lower level of H3K27me3 mark.
Although a limited sample size and unknown mutational states, patients
with high expression of FOXP2 displayed a shorter survival than FOXP2 low
patients when followed up to 30 months (Fig. 3.21A). To increase the power of
this analysis, we queried published RNA-sequencing data from the Cancer
Genome Atlas using KM-Plotter on 504 lung adenocarcinoma samples. Higher
EZH2 expression correlated with significantly worse prognosis in lung
adenocarcinoma up to 250 months after diagnosis (Fig. 3.21b and 3.21c).
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Moreover, higher FOXP2 expression correlated with significantly shorter overall
survival up to 30 months after diagnosis, and shorter relapse-free survival 250
months post diagnosis (Fig. 3.21d and 3.21e). In summary, in lung cancers, EZH2
expression decouples from PRC2 activity, and a pattern of high EZH2, low
H3K27me3 and high FOXP2 is enriched in poorly differentiated advanced lung
cancers, probably induced by their metabolic aberrations.

97

a

c

b

d

Figure 3. 19 EZH2 correlates with high FOXP2 expression, low H3K27me3 and
poorly differentiated lung tumors

(a) Representative images of lung adenocarcinoma specimens defined as well,
moderately, and poorly differentiated stained for the indicated markers, scale
bar=100µm. (b) Box and whisker plots depict percentage of positively stained
tumor nuclei in ADC, ADSCC, poorly differentiated tumor and SCC specimens for
the markers EZH2, H3K27me3 and FOXP2. (c) Correlation between EZH2 and
H3K27me3 (top) and EZH2 and FOXP2 (bottom) based on the percentage of
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positively stained tumor nuclei in primary lung cancer specimens. Pearson’s
correlation coefficients and p values are shown. (d) Average percentage of
positively stained tumor nuclei for the indicated markers in lung cancer specimens
defined as well, moderately, and poorly differentiated, * indicates p<0.043 and **
indicates p=0.004 by ANOVA with pairwise comparisons.
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Figure 3. 20 S-Adenosyl methionine regulates PRC2 stability and activity

(a) H460, (b) A549 and (c) BEAS-KP 2D cells with or without 500μM SAM
treatment for 6 days were examined for the expression of the indicated proteins
by immunoblot. H3 indicates total histone H3 and is the loading control. (d) 2D
Ezh2 wild-type UK803 with or without 500μM SAM treatment for 6 days were
examined for the expression of the indicated proteins by immunoblot. H3
indicates total histone H3 and is the loading control.
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Figure 3. 21 EZH2 and FOXP2 correlates with worse prognosis in lung
adenocarcinoma

(a) Kaplan-Meier survival curves for the FOXP2 high and FOXP2 low TMA
samples as measured by immunohistochemistry 30 months post diagnosis, groups
were split equally at median expression, p value was calculated by Mantel-Cox
log-rank test. (b) Kaplan-Meier overall survival curves and (c) relapse-free survival
curves for the EZH2 high and EZH2 low tumors as measured by RNA-sequencing
250 months post diagnosis, groups were split equally at best cut-off, p value was
calculated by Mantel-Cox log-rank test. (d) Kaplan-Meier relapse-free survival
curves and (e) overall survival curves for FOXP2 high and FOXP2 low tumors as
measured by RNA-sequencing 250 months post diagnosis, positive and negative
groups were determined by best cut-off, p value was calculated by Mantel-Cox logrank test.
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3.9

Summary and discussion
Here, we found that haplo- and full-insufficiency of the Polycomb

Repressive Complex 2 (PRC2) had divergent outcomes in KRAS-driven lung
cancers, further supporting the hypothesis that EZH2 can act as an oncogene or
tumor suppressor in different cellular contexts. Building upon previous findings of
de-coupling of EZH2 from PRC2 catalytic activity214,269-271, we discovered that
EZH2 and its enzymatic substrate H3K27me3 were inversely correlated in lung
adenocarcinoma samples, and that poorly differentiated tumors were often EZH2high/H3K27me3-low. Furthermore, while Ezh2 heterozygous lung tumors were
less aggressive than Ezh2 wild-type tumors, homozygous deletion of Ezh2
triggered a re-programming of tumors to an aggressive metastatic state
characterized by high expression of the embryonic transcription factor FOXP2. In
patient samples, FOXP2 expression predicted significantly shorter relapse-free
survival. Several previous studies have shown that loss of PRC2 activity can
reprogram cells into more aggressive states in medulloblastoma and lung
cancers100,214,305, suggesting that in many cancer settings, the most aggressive
state is characterized by a loss of PRC2 activity. Unlike a model that drove PRC2
loss through Eed deletion and observed acquisition of a mucinous phenotype100,
our Ezh2-deletion model did not have mucinous differentiation in vivo, suggesting
that a non-PRC2 role of EZH2 or the residual activity of PRC2-EZH1 may control
acquisition of the mucinous phenotype. Our data demonstrated that over-dose of
SAM could cause the degradation of EZH2 together with tri-methylation
accumulation, thus leading to the decoupling. Our future research is focused on
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understanding its physiological or pathophysiological metabolic mechanism
through which SAM supply is regulated, and whether this process can be reversed
for therapeutic intervention.
This interesting dosage effect of Ezh2 is distinct from cases where
heterozygosity shows genetic advantage, such as mutations in DICER, PTEN and
ARID1A306,307. Rather, in the case of Ezh2, heterozygous mutations may yield
decreased cell fitness and be selected against, thus never allowing the opportunity
for loss of heterozygosity that would yield the fully mutant phenotype we generated
here. Another case that may be similar is mono- vs. bi-allelic deletion of the
chromatin enzyme Setd2, which has both histone and non-histone substrates308.
It was found that mono-allelic Setd2-deficient cells retained histone methylation
(H3K36me3) but lost tubulin methylation (αTubK40me3), while bi-allelically
deficient cells lost both marks309. Non-histone substrates for PRC2 include talins
and the transcription factor STAT3310,311, and further studies could query if Ezh2
haploinsufficiency influences these functions. Regardless of the underlying
mechanism, this discovery suggests that unlike inhibitors targeting driver
oncogenes, a sub-maximal dose of EZH2 inhibition or a strategy to decrease
EZH2 protein level may target the most viable therapeutic window for lung cancer.
Furthermore, our data strongly suggest that a combination of EZH2
inhibition and BET inhibition will be synthetically lethal in KRAS-driven lung
cancers. Using both genetic manipulation and pharmacological approaches, we
observed that Ezh2-null tumor spheroids, allografts and autochthonous lung
tumors were sensitive to the BET inhibitor JQ1. Furthermore, there was strong
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synergy between the FDA-approved EZH2 inhibitor EPZ-6438 and JQ1 in a variety
of human lung cancer cells. Mechanistically, we identified that FOXP2, which was
previously identified as a key regulator of embryonic lung progenitor cells287 was
a modulator of response to BET inhibitors. We confirmed that FOXP2 was a direct
target of PRC2-mediated gene silencing in lung epithelial cells, and that enforced
expression of FOXP2 increased stemness and migration of lung epithelial cells.
These phenotypes were not unique to KRAS-mutated cells – FOXP2 overexpression in normal lung epithelium led to increased migration, increased growth
in Matrigel cultures and up-regulation of genes involved in RAS signaling. Our
research focused on KRAS+/TP53-null lung cancers, and whether the EZH2i/BETi
synergy will be viable in other major lung cancer genotypes will require further
research.
It is notable that our drug response findings and the identification of FOXP2
were discovered in vitro only due to the use of 3D tumor spheroid cultures. We
found that murine 2D cell lines had extremely high levels of S-phase and downregulation of genes involved in lung lineage determination when compared to 3D
tumor spheroids, which showed retention of lung specification transcriptional
programs. This finding is consistent with the belief that 3D cultures are able to
retain more characteristics of the native tissue from which they were derived, and
demonstrate the vast differences between the same cells cultured in two
dimensions versus those in three dimensions. The outcomes of loss of PRC2
activity in 3D and 2D cells were also divergent. In the Ezh2 null genotype, 2D cell
lines had marked de-repression of Hox genes, but in 3D tumor spheroids, Ezh2
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null cells were able to continue to repress Hox genes and instead showed derepression of Foxp2. Clearly, Hox genes are Polycomb targets in mammalian
cells297,312, but our studies suggest that in lung cancer cells, dysregulation of HOX
genes in PRC2-deficient settings may only happen in 2D cell lines. Other studies
have demonstrated that murine tumor spheroids can be used to build genetically
diverse bio-banks that can then be used for in vitro and in vivo studies including
immunotherapy studies313,314. Even with a traditional human 2D cell line, a recent
study demonstrated that a CRISPR-based screen identified more genes relevant
to human cancer when the screen was performed in 3D spheroid cultures226.
Together, these findings underscore the power of using 3D systems for genetic,
epigenetic and drug validation experimentation in cancer research.
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CHAPTER 4. EZH2 INHIBITION CONFERS PIK3CA-DRIVEN LUNG TUMORS
ENHANCED SENSITIVITY TO PI3K INHIBITION

4.1

Brief introduction
Large scale studies of tumor genetics have uncovered that alterations in the

Phosphoinositide 3-kinase (PI3K) pathway are prevalent in cancer.186 In particular,
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)
encoding the catalytic subunit p110α of the PI3K complex is highly mutated and
amplified in numerous cancer types, including lung cancer. The signaling pathways
downstream of PI3K include AKT and mTOR, and genetic alterations of PIK3CA
represent one of the oncogenic drivers of lung cancer, along with activating
mutations in EGFR and KRAS.315 Despite the recent development of specific PI3K
inhibitors, there is still no FDA-approved precision medicine option for this genetic
subclass of lung cancer. In fact, the early clinical trials of PI3K inhibitors on lung
cancers had underwhelming results and were ended early, though the patient
population included both patients with the activation of PIK3CA and those with
loss-of-function mutation in the PI3K negative regulator phosphatase and tensin
homolog (PTEN). 316-318

It is widely believed that in addition to genetic mutations, epigenetic
changes may be required for maintenance of the cancer cells in proliferative and
drug-resistant states. One attractive way to target tumor-related growth programs
is through inhibition of epigenetic regulators of gene expression. A group of master
regulators of chromatin state in stem cells and cancers are termed the Polycomb
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Repressive Complexes (PRCs)319. Research has shown that histone methylation
or ubiquitylation mediated by these PRCs can affect higher order chromatin
structure, rendering areas in the genome inaccessible to transcriptional
machinery320. Specifically, the complex PRC2 often contains EZH2 as the
methyltransferase that tri-methylates histone H3 at lysine 27 (H3K27me3),
silencing gene expression319,321 Recently, a small molecule inhibitor of the
epigenetic histone methyltransferase EZH2, tazemetostat, was FDA-approved in
solid tumors including epithelioid sarcoma and follicular lymphoma, and several
others are being used in pre-clinical models and clinical trials.322 While some data
have suggested that EZH2 inhibitors will synergize with immunotherapies or other
chemotherapies, it is unknown if tumors mutant for the PI3K pathway would benefit
from it. Furthermore, it also remains unknown if PI3K inhibitors will synergize well
with EZH2 inhibitors in lung cancer.

In this study, we reveal that the PIK3CA-mutant or amplified lung cancer
cells were more sensitive to EZH2 inhibition. PIK3CA E545K, the most common
mutation in lung cancer, presents a modest transformation capacity along with p53
loss in lung epithelial cells, and drove lung adenocarcinoma formation
autochthonously. Also, we discover that EZH2 inhibition synergized with PI3K
inhibition in human cancer cells in vitro and in vivo. This study sheds light on a
promising combinatorial therapy for patients with PIK3CA mutated or amplified
lung cancer.

107

4.2

PIK3CA mutated or amplified cell lines have increased sensitivity to EZH2
inhibition
We first queried the cBioportal database to understand the current

landscape of PIK3CA mutations in lung cancer patients.323,324 Leveraging data
from The Cancer Genome Atlas (TCGA) pan-lung cancer dataset, we observed
that 24% of lung tumors harbored PIK3CA alterations, the majority of which were
gene amplifications with or without missense mutations (Figure 4.1a). Strikingly,
this patient subset was nearly mutually exclusive to those with KRAS genetic
alterations (log2 odds ratio -1.819, q-value <0.0001), the latter of which were
mainly missense mutations. Overall, 509 (44%) out of the 1144 samples queried
had genetic aberrations in either PIK3CA or KRAS, or both. Among these patients,
lung adenocarcinoma (LADC) predominantly harbored genetic mutations, which
were mainly KRAS mutations. (Figure 4.1b) On the contrary, the majority of lung
squamous cell carcinoma (LSCC) samples had amplifying PIK3CA. Although
LADC had a much lower frequency of PIK3CA alterations, the proportion of
PIK3CA mutations were relative higher than the amplification in LADC. The most
common mutation in PIK3CA genetic region is a point mutation that yields a
substitution of glutamic acid by lysine at position 545 and this specific change
(PIK3CA E545K) was observed in 29 (10.5%) of patients with PI3K alterations
(Figure 4.1c).

In order to test the effects of EZH2 inhibition on lung cancer cells with
differing PIK3CA and KRAS statuses, we screened 16 lines for sensitivity to the
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EZH2 inhibitor GSK126. All the cell lines with IC50 values below 7µM were reported
to be PIK3CA mutant or amplified (Figure 4.2). In contrast, the cell lines mutant
for KRAS or NRAS, but without any known alteration of PIK3CA had higher IC50
values, up to 17.4µM, for GSK126. Two cell lines, H2126 and H520, do not have
mutations in either RAS or PIK3CA and those cell lines had intermediate IC50
values. Overall, PIK3CA mutant and amplified cell lines had an average IC50 value
of 6.1µM, while cell lines mutant for RAS and wild-type (WT) for PIK3CA had an
average IC50 value of 10.6µM, a 1.74-fold difference (Figure 4.2). This result
suggests a window of vulnerability for PI3K-driven cancers to be targeted by EZH2
inhibition. There were two notable exceptions to the genotype-sensitivity
correlation in our dataset, H460 and H1975. H460, which has a PIK3CA E545K
mutation, also harbors a mutation in LKB1/STK11, which through AMPK activates
downstream mTOR signaling as PI3K does. In addition, H1975, an EGFR-driven
line, which is also PIK3CA mutant and LKB1 mutant, appears to be insensitive to
GSK126. None of the GSK126-sensitive cell lines have LKB1 mutations, implying
the combination of mutant/amplified PIK3CA and WT LKB1 may be the most
responsive to EZH2i.
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Figure 4. 1 Landscape of PIK3CA mutations in lung cancer patients

(a) Landscape of PIK3CA and KRAS gene alterations in cBioPortal database
showing 1144 non-small cell lung cancer patients. (b) Alteration frequencies of
PIK3CA and KRAS in LADC and LSCC from cBioportal database. (c) Lollipop plots
of each annotated mutations located in PIK3CA or KRAS coding regions.
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Figure 4. 2 PIK3CA mutated or amplified cell lines have increased sensitivity to
EZH2 inhibition

Non-linear regression of cell line survival in response to the EZH2 inhibitor
GSK126 is plotted for each cell line separately (left) and three groups as indicated
(right), p<0.001 in PIK3CA Mut/Amp vs. Ras Mut/PIK3CA WT.
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4.3

PIK3CA-E545K induces moderate transformation in lung epithelial cells
We next sought to learn about the oncogenic potential of the most common

mutation of PIK3CA in lung cancer, PIK3CA-E545K. BEAS2B cells are
immortalized with SV40, and therefore should have inactivation of both RB and
p53 pathways.325 We first introduced a mutated form of p53, p53-R175H, to
BEAS2B cells to both ensure that WT p53 function is completely abrogated and to
possibly introduce some gain-of-function roles of mutant p53, and we used this as
our base cell line.326 We then inserted either WT PIK3CA, mutated PIK3CAE545K, or mutated KRAS-G12V into the base lines (Figure 4.3a) The integration
of the vectors was confirmed by PCR of genomic DNA with primers that included
a region specific to the targeting virus (Figure 4.3b). We next tested the functional
activity of PI3K pathway in these modified BEAS2B lines by detecting phosphoAKT/total AKT ratio downstream of PI3K. Immunoblots showed that BEAS2B with
PIK3CA-E545K insertion had drastically increased level of phospho-AKT than the
control empty vector (Figure 4.3c). Introduction of WT PIK3CA and KRAS-G12V
slightly upregulated phospho-AKT. Calu3, a lung cancer cell line with PIK3CA
amplification and p53 mutation, had the highest AKT phosphorylation level of all
cell lines tested.

To dissect the transformation capacity of PIK3CA-WT, PIK3CA-E545K and
KRAS-G12V, we performed soft agar colony formation assay on these four lines.
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It showed that KRAS-G12V-transformed BEAS2B cells formed many more
colonies than the other three cell lines, though due to variability of the experiment
the normalized data were not significant (Figure 4.4a and 4.4b). PIK3CA-E545K
cells yielded slightly more colonies than the control and PIK3CA-WT BEAS2B
cells, but again this result was not significant. However, in 3-dimensional (3D)
Matrigel culture, KRAS-G12V cells yielded the most organoids and both PIK3CAE545K and KRAS-G12V lines developed significantly more organoids than the
control cells (Figure 4.5a and 4.5b). There were no obvious differences in
organoid counts between control and PIK3CA-WT cells. Together, these findings
suggest a modest transformation capacity of PIK3CA-E545K mutation in lung
epithelial cells.
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Figure 4. 3 PIK3CA-E545K mutation activates downstream pathways in lung
epithelial cells

(a) Schematic of modifications in BEAS2B cells with indicated vector introduction.
(b) Recombination PRC of genomic DNA with primers covering a region specific
to the targeting virus indicated. (c) Immunoblot probing phospho-AKT and total
AKT protein expression from the cell lysate indicated.
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Figure 4. 4 PIK3CA-E545K does not affect colony formation in soft agar in lung
epithelial cells

(a) Representative whole well images and (b) colony counts of soft agar colony
formation assay with the modified BEAS2B cells indicated.
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Figure 4. 5 PIK3CA-E545K induces moderate transformation in lung epithelial
cells in 3D Matrigel culture

(a) Representative whole well images and (b) colony counts of 3D Matrigel culture
with the modified BEAS2B cells indicated.
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4.4

Pik3ca-E545K with p53 loss drives lung adenocarcinomas in a novel mouse
model
Next, in order to study the role of PIK3CA E545K mutation in the

tumorigenesis in vivo, we obtained the genetically engineered mouse model
(GEMM) that harbored floxed alleles of Trp53 and a Lox-stop-Lox conditional
activating allele encoding Pik3ca-E545K knocked into the endogenous Pik3ca
(Figure 4.6a). We administered adeno-Cre virus via intranasal instillation to
cohorts of mice and Monitored mice for signs of tumor burden. At more than 52weeks post adeno-Cre, five out of seven mice analyzed (71.4%) had frank lung
tumors that were uniformly adenocarcinoma by histological examination (Figure
4.6b, 4.7a and 4.7b). These tumors had high expression of pro-surfactant protein
C (SPC) and no detectable expression of acetylated tubulin, KRT5, SOX2 or club
cell secretory protein (CCSP), suggesting that the tumors were adenocarcinoma
probably originated from alveolar type 2 (AT2) progenitor cells. Some tumors had
light and sporadic staining for MUC5AC, but no obvious goblet cell differentiation.
The antibodies used were validated on tracheal and esophagus sections (Figure
4.7c). The prolonged latency of this model compared with Kras-G12D/p53-loss
mouse model is consistent with our results in the BEAS2B cell line, suggesting that
PIK3CA-E545K is a relatively weak oncogene relative to oncogenic KRAS. It was
also accordant with the observation that PIK3CA mutations were more frequently
seen than amplified PIK3CA in LADC, in spite of the prevalence of PIK3CA
alterations, mainly amplifications, in LSCC.
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We next isolated tumor cells from the Pik3ca/p53 GEMMs and grew the
cells in specialized air-liquid-interphase 3D Matrigel cultures. These types of
cultures have allowed for successful propagation of every murine lung cancer
model so far studied, including Kras-G12D/Trp53-null, Kras-G12D/Lkb1-null,
EGFR-L858R/T790M

and

Lkb1-null/Pten-null

tumor

models.

Initially

the

Pik3ca/p53 tumor cells grew as organoids that resembled the structure of lung
alveoli. Upon passaging, it was clear that the model did not have the robust growth
capacity observed from our other tumor models. Given the alveolar structure of the
tumor organoids, we reasoned that they may grow better with neonatal lung
mesenchymal cells, which help to support alveolar cells. Co-culturing with these
mesenchymal cells, either as a monolayer on the bottom of the transwell or mixed
into Matrigel, allowed for improved growth of the tumor cells so that several models
could be established (Figure 4.8). These models will be important for future drug
studies. Altogether, Pik3ca E545K mutation with p53 loss drove lung
adenocarcinoma in vivo with a moderate oncogenic property.
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Figure 4. 6 Pik3ca-E545K with p53 loss drives lung cancer in a novel mouse
model
(a) Schematic of Pik3ca-E545K LSL/+;Trp53 fl/fl cohorts of mouse models. (b) Tumorfree survival of mice of the Pik3ca/p53 mice.
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Figure 4. 7 Pik3ca-E545K with p53 loss drives autochthonous LADC

(a) H&E and IF analysis with the indicated probes of Pik3ca-E545K

LSL/+

;Trp53

fl/fl

murine tumor sections 55 weeks post infection. (b) H&E and IF analysis with the
indicated probes of Pik3ca-E545K

LSL/+

;Trp53

fl/fl

murine tumor sections 64 weeks

post infection. (c) Antibody validation of IF analysis with the indicated probes of
Pik3ca-E545K LSL/+;Trp53 fl/fl murine tracheal and esophagus sections.
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Figure 4. 8 Pik3ca-E545K/p53-loss tumors form alveolar tumor organoids

Microscopic images of 3D organotypic cultures of Pik3ca-E545K
murine tumors
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4.5

EZH2 inhibition synergizes with PI3K inhibition in lung cancer
Given the significant increase in sensitivity of PIK3CA mutant/amplified lung

cancer cells to EZH2 inhibitor GSK126, we reasoned that a combination of the
PI3K inhibitors, such as copanlisib, and the EZH2 inhibitors could allow for a more
potent therapeutic response. During the course of our studies, the EZH2 inhibitor
tazemetostat (EPZ-6438) became FDA approved and therefore, we included this
second EZH2 inhibitor in our drug synergy studies. We identified that both GSK126
and EPZ-6438 were very effective at reducing the PRC2 histone mark, H3K27me3,
and that copanlisib was very effective at reducing the levels of phospho-AKT in
both Calu3 and Sw1573 lung cancer cells(Figure 4.9a). Of note, Sw1573 cells
have PIK3CA-K111E and KRAS-G12C mutations, while Calu3 cells have PIK3CAamplification but no RAS mutation and showed substantially higher phospho-AKT
than Sw1573. Intriguingly, copanlisib combined with EPZ-6438 led to a lower level
of phospho-AKT than copanlisib alone or combined with GSK126.

In order to examine the synergy of EZH2 inhibitor and PI3K inhibition, we
performed dose synergy matrix experiments and analyzed the data with
SynergyFinder2.0.249 The results showed that copanlisib had synergistic effect
with EZH2 inhibitors GSK126 and EPZ-6438 in both Calu3 and Sw1573 cells
(Figure 4.9b). Next, we studied it in BEAS2B cells with control empty vector,
PIK3CA WT, E545K mutation, or mutated KRAS-G12V. It showed that PIK3CA
WT or mutation did not change the sensitivity to GSK126, while KRAS mutation
conferred resistance to GSK126 in BEAS2B cells (Figure 4.10). Moreover,
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copanlisib synergized with GSK126 and EPZ-6438 in all the modified BEAS2B
cells except for copanlisib with EPZ-6438 in KRAS-G12V line, which showed an
antagonistic effect (Figure 4.11a and 4.11b). Mechanistically, EZH2 inhibitors and
PI3K inhibitor all raised the mRNA expression of PI3K interacting protein 1
(PIK3IP1), a negative regulator of PI3K by binding to the p110 catalytic subunit of
PI3K and suppressing it activity.327 Combining copanlisib with GSK126 or EPZ6438 induced a higher expression of PIK3IP1 in Calu3, Sw1573 and all the
BEAS2B lines (Figure 4.12a and 4.12b). To validate the use of this drug
combination in vivo, we administered four treatment arms including vehicle,
copanlisib, EPZ-6438 and copanlisib combined with EPZ-6438 (combo) to mice
harboring Calu3 xenografts. IHC analysis confirmed that H3K27me3 was
decreased in the EPZ-6438 and combo treated xenografts (Figure 4.13a). After
10 days of treatment, tumor growth was significantly slower in copanlisib, EPZ6438 and combo treated mice compared with vehicle (Figure 4.13b). Importantly,
combo treated xenograft tumors were also significantly smaller than the copanlisib
or EPZ-6438 alone, demonstrating a collaborative effect of these two drugs in vivo.
Together, these results reveal a promising combination therapy of EZH2 inhibition
with PI3K inhibition to target lung cancers with PIK3CA genetic alterations.
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Figure 4. 9 EZH2 inhibition synergizes with PI3K inhibition in lung cancer cell
lines in vitro

(A) Immunoblots of indicated proteins in Calu3 and Sw1573 cells with vehicle,
GSK126, EPZ-6438, copanlisib, GSK126+copanlisib and EPZ-6438+copanlisib,
respectively. (B) Heatmap of Bliss synergy scores of GSK126 combined with
copanlisib, EPZ-6438 combined with copanlisib in Calu3 and Sw1573 used to
produce an average matrix. Overall Bliss scores with 95% confidence intervals
were 4.7+/-2.2, 8.1+/-1.4, 2.6+-5.9, and 4.8+/-3.5, respectively. Most synergist
area Bliss scores were 12.0, 12.3, 10.9 and 7.1, respectively.
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Figure 4. 10 PIK3CA WT and E545K do not change sensitivity to GSK126 in lung
epithelial cells

Dose responses of the indicated BEAS2B cell lines treated with GSK126,
p<0.0001 KRAS-G12V compared with empty vector.
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Figure 4. 11 EZH2 inhibition synergizes with PI3K inhibition in lung epithelial cells
with or without PIK3CA mutation in vitro
(a) Heatmap of Bliss synergy scores of GSK126 combined with copanlisib in the
indicated BEAS2B cell lines used to produce an average matrix. Overall Bliss
scores with 95% confidence intervals were 8.2+/-3.9, 10.3+-4.2, 5.5+-3.3, and
6.8+-3.7, respectively. Most synergist area Bliss scores were 13.5, 16.3, 11.1, and
12.3, respectively. (b) Heatmap of Bliss synergy scores of EPZ-6438 combined
with copanlisib in the indicated BEAS2B cell lines used to produce an average
matrix. Overall Bliss scores with 95% confidence intervals were 7.1+-2.6, 5.7+-1.7,
9.4+-3.4, and -5.6+-3.0, respectively. Most synergist area Bliss scores were 9.35,
8.5, 11.7, and -1.54, respectively.
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Figure 4. 12 EZH2 inhibition and PI3K inhibition reduce PIK3IP1 expression

(a) Relative mRNA expression of PIK3IP1 in Calu3 and Sw1573 cells with the
indicated treatments. (b) Relative mRNA expression of PIK3IP1 with treatment of
vehicle,

GSK126,

EPZ-6438,

copanlisib,

6438+copanlisib in the indicated BEAS2B cells.
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Figure 4. 13 EZH2 inhibition cooperates with PI3K inhibition in lung cancer cells
in vivo

(a) Representative images of H3K27me3 IHC staining in the Calu3 xenografts with
the indicated treatment. (b) Percentage of tumor growth relative to Day0 for 10
consecutive days with the indicated treatment.
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4.6

Summary and discussion
PI3K inhibitors in clinical trials did not show robust anti-tumor effect in lung

cancer.316-318,328 This study shows that PIK3CA mutation is a moderate oncogene
with weak transformation capacity compared with KRAS mutation, which suggests
that cancer cells may not heavily rely on the PI3K pathway, especially when
negative regulators such as PTEN are intact or bypath activation of PI3K
downstream targets exist. This might be the reason why PI3K inhibitors have not
been shown promising results in clinical trials. Similarly, other studies found
PIK3CA-H1047R was also a weak oncogene on its own in breast cancer, but it
could cooperate with other oncogenic lesions, such as partial loss of the tumor
suppressor APC.329 Our research is the first time to describe the oncogenic
property of PIK3CA E545K, the most prevalent mutation in lung cancer.
Furthermore, there are some other therapies showing cooperative effect with PI3K
inhibition, including combinations with receptor tyrosine kinase inhibitors,
endocrine therapies, mTOR inhibitors, MEK inhibitors and DNA damaging
chemotherapies.330 Discovery of novel combinatorial strategies may improve the
efficacy of PI3K inhibitors in lung cancer.

The mechanisms of PI3K inhibition synergizing with EZH2 inhibition need
further study. We showed a possible mechanism that PI3K inhibition or EZH2
inhibition alone could both increase the expression of PI3K negative regulator
PIK3IP1, and combining these two strategies induced a more robust upregulation
of PIK3IP1. It is consistent with the immunoblot result which showed copanlisib
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combined with EPZ-6438 led to a lower phospho-AKT compared with copanlisib
alone. However, such decrease in phospho-AKT was not observed in copanlisibGSK126 combined treatment. Thus, we could not exclude the possibility of
GSK126-induced toxicity in this scenario. In the future, we propose to perform
RNA-sequencings on the cells treated with the four arms to help discover other
novel mechanisms to explain the synergy combining EZH2 inhibitor with PI3K
inhibitor.

The reason why PIK3CA E545K mutation generated LADC but not LSCC
remains unknown. The result of adenocarcinoma formation was consistent with
the cBioportal results that LADC harbored more PIK3CA mutations than amplified
PIK3CA, while most of the LSCC samples had PIK3CA amplification, not PIK3CA
mutations. PIK3CA mutation or amplification may have distinct molecular targets
driving different programs of tumor initiating and progression. Such difference was
also reported in HER-2 positive lung cancer.331 Mutation or amplification of PIK3CA
may also transform different cells-of-origin, like AT2 cells or basal cells
respectively, which requires further investigation in different stem or progenitor
cells.332 PI3K pathway was also found to have important roles in embryonic
development and cell fate determination.333 Therefore, understanding of such
difference will help define the appropriate target patients for PI3K inhibitor.
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CHAPTER 5. EPIGENETIC STATE DETERMINES SENSITIVITY OF EGFRDRIVEN LUNG CANCER CELLS TO THERAPY

5.1

Brief introduction
Understanding the cellular and molecular origins of lung cancer will help

define ways to prevent this deadly disease. Different stem or progenitor cells of
adult lung reside throughout the trachea to the distal alveoli, including basal cells
and club cells in the proximal airways, bronchioalveolar stem cells (BASCs) and
alveolar type 2 (AT2) cells in the distal airways

213,229,230

. Lung adenocarcinoma

has been postulated to originate from club cells, AT2 cells or BASCs, while
squamous cell carcinomas likely arise from basal cells 334-336. Experimental models
have shown that given different oncogenes, lung cells can be more or less ‘fit’ to
form fully malignant lesions 248,337,338. However, the cellular origins for the majority
of lung cancers have not been clarified yet. Determining common lung tumor
origins may help us to understand how to prevent malignant transformation, and
guide us to using appropriate therapeutics.

Precision medicine options for lung cancer have greatly expanded in the
past decade. Biomarkers encoded by genetic changes are currently the
predominant tools for deciding precision medicine options. However, epigenetic
biomarkers, including markers of cell states, could add crucial additional
predictions of drug responses. As an example, for lung adenocarcinoma there are
at least three distinct reproducible subtypes that have been identified through
transcriptomics approaches, and each of these subtypes may have not only
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genetic, but also epigenetic determinants of drug response. 339 These three
subtypes have been termed bronchoid, magnoid and squamoid. From the
perspective of lung epithelial cell types, squamoid may represent bronchiolar
epithelial cells including SOX2+ secretory club cells or basal cells, while bronchoid
may represent more distal alveolar type 2 cells. Bronchoid tumors tend to be more
acinar and better prognosis, while squamoid have more solid pattern and worse
prognosis. Magnoid tumors are characterized by high cell cycle and poorer
prognosis. Transcriptionally distinct subtypes may provide an additional layer of
guidance for prognosis or therapeutics in clinics.

One of the most successful precision medicine options for lung cancer
patients is targeting the epidermal growth factor receptor (EGFR) with drugs that
inhibit the tyrosine kinase function of the activated protein 340. Gefitinib was the first
EGFR inhibitor, followed quickly by erlotinib, but both inhibitors were plagued by
development of drug resistance, in many cases through mutation of the T790M
gatekeeper residue of EGFR 128,341.

Second generation irreversible and third

generation mutant-selective inhibitors including afatinib, osimertinib and rociletinib
were developed

342

. Most recently, the third generation TKI osimertinib has been

moved to a first line agent for EGFR mutant lung cancer134. However, acquired
resistance to osimertinib has also emerged in patients potentially resulting from
EGFR mutations (C797S, G724S, L718Q), loss of T790M, pathway bypass
through KRAS, MET or PIK3CA activation or small-cell lung cancer transformation
179-181

.
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Here we describe a model of EGFR-driven lung cancer and a method to
develop tumors of distinct epigenetic states through the use of three-dimensional
(3D) organotypic cultures. We discovered that EGFR mutation led to lung cancer
with alveolar or bronchiolar features, which can originate from AT2 cells or BASCs,
but not basal cells or club cells of the trachea. We also demonstrate that these
clones were able to retain their epigenetic differences through passaging
orthotopically in mice, and crucially that they had distinct drug vulnerabilities that
can be modulated through drug combinations. This work serves as a blueprint for
exploring how epigenetics can be used to stratify patients for precision medicine
decisions.

5.2

The autochthonous LSL:EGFR T790M/L858R model develops lung
adenocarcinoma in mice
To interrogate the cell-of-origin for EGFR-driven lung cancer, we utilized a

model generated by knocking in the human EGFR gene encoding protein with both
T790M and L858R mutations (EGFR TL) into the Collagen1a1 (Col1a1) locus
(Figure 5.1a). The EGFR TL mutations were used in the model because patients
usually had L858R mutation firstly and acquired the second T790M mutation to
become resistant to first or second generation TKIs. The resulting mice contain
one Col1a1 locus that had been replaced with a lox-stop-lox cassette followed by
the CAG promoter and a mutant EGFR gene. Cre-mediated deletion of the loxstop-lox site was accomplished by intranasal instillation of adeno-Cre virus, which
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infects random cells from the proximal to distal airways. The median of the tumorfree survival in this model was 107 days, 120 days for males and 107 days for
females with no statistical difference between the males and females (Figure
5.1b). The tumors that formed by intranasal adeno-Cre installation were almost
exclusively alveolar type adenocarcinoma, with rare tumor types exhibiting
bronchiolar features according to their immunofluorescence (IF) staining, although
it is difficult to distinguish them by their histological morphologies (Figure 5.1C and
5.2). Using IF staining, we demonstrated that majority of the tumors expressed the
AT2 cell marker pro-surfactant protein C (proSPC), while rare tumors also had
expression of club cell secretory protein (CCSP) or the bronchiolar transcription
factor SOX2. It is similar with the previous study in EGFR TL mice, in which the
tumors were termed as bronchial and peripheral 343.
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Figure 5. 1 The autochthonous LSL:EGFR T790M/L858R model develops lung
cancer in mice

(a) Schematic of mouse model with LoxP-mediated activation of EGFR
T790M/L858R mutations. (b) Overall survival of mice of the indicated gender is
graphed, n=7 male, n=13 female. (c) Representative H&E stained cross sections
from lungs of EGFR T790M/L858R autochthonous model.
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Figure 5. 2 The autochthonous LSL:EGFR T790M/L858R model develops lung
adenocarcinoma with alveolar or bronchiolar features in mice
Representative

immunofluorescence

staining

of

autochthonous lung tumors with the indicated probes.
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5.3

Distal lung stem/progenitor cells efficiently undergo ex vivo malignant
transformation by mutant EGFR
Next, in order to understand if there are different cells in the normal lung

epithelium that can serve as cells of origin for the EGFR-driven lung cancers, we
used our in vitro transformation strategy 248. Lungs and tracheas from non-tumor
bearing mice were isolated and the cells were dissociated and sorted for Nerve
Growth Factor Receptor (NGFR)+ basal cells of the trachea, NGFR- club cells of
the trachea, Stem Cell Antigen 1 (Sca1/LY6A)+ BASCs of the distal lung and Sca1AT2 cells of the distal lung (Figure 5.3a). FACS-isolated lung cells were then
divided into two aliquots, one of which received Adeno-GFP control virus, and the
other one received Adeno-Cre virus to activate mutant EGFR (Figure 5.3b). The
cell populations were then plated into 3D Matrigel organotypic cultures which also
contained neonatal lung mesenchymal endothelial cells as supporting cells
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.

Organoids post viral infection were allowed to grow and then were passaged.
Organoids from each cell population tolerated the activation of EGFR TL mutations
and continued to grow. During passages, organoids derived from BASCs were
manually subcloned into alveolar, bronchiolar and mixed cultures by their
microscopic morphologies. Mixed BASCs had both alveolar and bronchiolar
organoids (Figure 5.4). Then, the four subtypes of organoids infected by Ad-Cre
virus were orthotopically injected to the lungs of immunocompromised mice to
allow for further in vivo transformation. The mice started to show signs of lung
tumors 8 months post transplantation of AT2 cells or BASCs, including the
bronchiolar, alveolar and the mixed BASC organoids (Figure 5.5a). Only one
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mouse developed a small tumor nodule from tracheal club cell-derived
transplantation (Figure 5.5b). None of the mice that received basal cell-derived
organoids had tumors at sacrifice. Due to these differences, mice transplanted with
distal lung (BASC and AT2) organoids had a significantly shorter lung-tumor free
survival than the proximal lung/trachea (basal cell and club cell) organoid
transplantation (Figure 5.5c). Bronchiolar BASCs and AT2 cells formed tumors
with a higher tumor burden than the other organoid types, although high
heterogeneity existed among each mouse (Figure 5.5d).

Next, we analyzed the histology of the transformed tumors to study whether
the tumors maintained their original lineage properties during in vivo transformation.
It showed that most of the BASCs and AT2 derived tumors formed alveolar tumors
in vivo, with positive staining of alveolar marker SPC and barely any expression of
bronchiolar markers CCSP, SOX2 or the basal cell marker KRT5 (Figure 5.6).
Bronchiolar BASCs formed a small number of orthotopic bronchiolar tumor
nodules, although majority of the other tumors displayed positive staining of
alveolar lineage marker. It suggested that a large part of the bronchiolar BASCs
underwent lineage switch to alveolar state during transformation, probably due to
the impact of specific microenvironment in which it may be easier for alveolar cells
to reside. Altogether, these results suggested that the AT2 cells and BASCs were
the main cellular origins of EGFR mutant lung cancer, and these tumors retained
the innate properties of their derived stem or progenitor cells during the process of
tumorigenesis.
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Figure 5. 3 Schematic of cell-of-origin study in lung stem or progenitor cells
(a) Schematic of sorted for NGFR+ basal cells of the trachea, NGFR- club cells of
the trachea, Sca1/Ly6A+ BASCs of the distal lung and Sca1- AT2 cells of the distal
lung. (b) Schematic of cell-of-origin study in lung stem or progenitor cells including
FASC-sorting, in vitro propagation and adenovirus activation of EGFR, in vivo
orthotopic transplantation, and secondary in vitro culture.
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Figure 5. 4 BASC-derived EGFR-activated organoids form alveolar and
bronchiolar architectures in 3D culture

H&E and IF analysis of BASC-derived mixed organoids stained with the indicated
probes.
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Figure 5. 5 Distal lung stem/progenitor cells efficiently undergo ex vivo malignant
transformation by mutant EGFR

(a) Tumor-free survival of immunocompromised mice with the indicated
transplanted organoid types. (b) Tumor counts from each mouse with indicated
organoid types transplanted. (c) Tumor-free survival of immunocompromised mice
in the two groups of distal lung and proximal lung/tracheal derived organoids,
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p<0.001 between organoids from distal lung (lung) and proximal lung (trachea) by
Mantel-Cox log-rank test. (d) Tumor burden as percentage of total lung was
analyzed by ImageJ for indicated organoid types.

142

Figure 5. 6 BASC and AT2 derived organoids develop ex vivo transformed
tumors with distinct lineage features

H&E and IF analysis of orthotopic transformed bronchiolar and alveolar tumors
stained with the indicated probes.
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5.4

Different stem/progenitor cells drive distinct gene expression during
malignant transformation
In order to understand the deeper mechanisms of tumorigenesis and

progression induced by EGFR TL mutation, we performed RNA-sequencings on
the various stem/progenitor cell-derived organoids with Ad-GFP or Ad-Cre virus
and also tumor cells after orthotopic transplant (Figure 5.7a). To make sure
equivalent RNA samples were being compared, the transplanted tumors were
dissociated and propagated in 3D Matrigel culture in vitro prior to RNA extraction.
IF staining of the lineage markers showed that tumoroids from alveolar tumors
highly expressed alveolar marker SPC with no or low expression of bronchiolar
markers CCSP and SOX2, and the basal cell marker KRT5, while the bronchiolar
tumoroids, which were only obtained from bronchiolar BASC-derived transplants,
expressed in the opposite pattern (Figure 5.7b). This result suggest that tumor
cells retain their intrinsic lineage properties when propagating in vitro.

Hierarchical cluster analysis showed that post-transplant tumoroids
clustered together, away from the pre-transplant organoids (Figure 5.8a).
Intriguingly, tumoroids from an in vivo autochthonous tumor were transcriptionally
closer to mixed BASC-derived and AT2-derived tumoroids. To understand the
transcriptional alterations happened during the transformation by EGFR
T790M/L858R mutation in vitro and in vivo, we compared the gene expression on
the organoids with Ad-GFP or Ad-Cre virus infection and before or after
transplantation. The Gene Set Enrichment Analysis (GSEA) demonstrated that
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activation of EGFR mutations in distal lung cells led to significant enrichment of
genes associated with epithelial-mesenchymal transition (EMT), Hedgehog
signaling, TGF-β, KRAS and also EGFR pathways. Activation of EGFR mutations
in proximal lung/tracheal cells caused enriched hallmarks of KRAS, E2F targets,
G2M checkpoints, MTORC1 and AKT pathways (Figure 5.8b). EGFR pathway
was not significantly enriched in the proximal lung organoids after EGFR activation.
Within the distal lung epithelia, BASC-derived Ad-Cre organoids generally had
higher gene expression in MYC targets, E2F targets, interferon-α response, G2M
checkpoints, mutant p53 and EGFR pathways and lower expression of EMT and
vascular endothelial growth factor-A (VEGF-A) signatures than the AT2-derived
Ad-Cre organoids (Figure 5.9a).

Then, to further study the tumorigenic mechanisms during orthotopic
transformation, we compared BASC- and AT2-derived tumoroids post-transplant
with pre-transplant. Although the pre- and post-transplant samples were
sequenced at different platforms, principal component analysis (PCA) did not
detect obvious confounding variables separating these two platforms. GSEA
results then indicated that the gene sets relevant to MYC targets, MTORC1
signaling, DNA repair and deletion of RB were accumulated in post-transplant
tumoroids than pre-transplant, while EMT, EGFR and KRAS upregulated gene
signatures were less enriched (Figure 5.9b). Genes repressed upon knockdown
of EED and EZH2 in human fibroblasts were upregulated in post-transplant
tumoroids, suggesting that enzymatic function of Polycomb Repressive Complex
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2 (PRC2) may be increased during the orthotopic transplantation. These signaling
pathways regulated during the in vivo transformation may serve as potential
therapeutic targets combined with EGFR inhibition.

Furthermore, to interrogate the difference between bronchiolar and alveolar
tumors, we then compared the transcriptional phenotypes of bronchiolar tumoroids
derived from BASCs with alveolar tumoroids from either BASCs or AT2 cells
according to the expression of their lineage markers. GSEA results demonstrated
that bronchiolar tumoroids had transcriptional enrichment in TNF-α, KRAS,
mutated p53, EGFR, BMI1 deletion and PRC2 activity associated pathways than
alveolar tumoroids (Figure 5.9c). Conversely, alveolar tumoroids expressed
higher E2F targets and G2M checkpoint genes than bronchiolar. Together, these
data displayed that in vitro activation of EGFR T790M/L858R mutations and in vivo
orthotopic transformation drove distinct transcriptional landscapes in cells with
different cellular origins.
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a

b

Figure 5. 7 Schematic of RNA-sequencing analysis from different stages of
organoids and tumoroids
(a) Schematic of RNA-sequencing samples from organoids with indicated
treatment. (b) H&E and IF analysis of AT2-derived alveolar and BASC-derived
bronchiolar tumoroids after transplant stained with the indicated probes.
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a

b

Figure 5. 8 Different stem/progenitor cells drive distinct gene expression during
malignant transformation

(a) Hierarchical clustering and dendsort plot using principal component analysis of
the variability of gene expression of the indicated samples. (b) Bar plots of
normalized enrichment scores of selected gene signatures enriched in Ad-Cre
treated distal lung (left) or proximal trachea (right) organoids relative to Ad-GFP
treated organoids, with FDR q-values indicated outside the end of bars.
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a

b

c

Figure 5. 9 AT2 and BASC derived EGFR-mutant cells are transcriptionally
different
(a) Bar plots of normalized enrichment scores of selected gene signatures
enriched in BASC-derived organoids relative to AT2-derived Ad-Cre treated
organoids, with FDR q-values indicated outside the end of bars. (b) Bar plots of
normalized enrichment scores of selected gene signatures enriched in tumoroids
after transplant relative to Ad-Cre treated organoids before transplant, with FDR q149

values indicated outside the end of bars. (c) Bar plots of normalized enrichment
scores of selected gene signatures enriched in bronchiolar tumoroids relative to
alveolar tumoroids, with FDR q-values indicated outside the end of bars.
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5.5

Bronchiolar and alveolar tumoroids respond to therapies differentially
Next, to interrogate whether tumors with different cell fates have distinct

sensitivities to therapies, especially tyrosine kinase inhibitors (TKIs), we performed
dose-response assessment on the bronchiolar and alveolar 3D tumoroids. First,
we confirmed the expression of lineage markers of these tumoroids by RT-qPCR.
It showed BASC-derived bronchiolar (BASC-B) tumoroids had significantly lower
expression of alveolar marker Sftpc, higher expression of club cell marker Scgb1a1
and proximal lung epithelial markers including Sox2, Trp63, Krt5 and Foxj1 than
the AT2-derived alveolar (AT2-A) tumoroids (Figure 5.10a). Intriguingly, BASCderived alveolar (BASC-A) tumoroids from alveolar tumors expressed both
Scgb1a1 and modest Sftpc, together with expression of the proximal airway
lineage markers Trp63 and Krt5. It suggested that BASC-A cells may be in a mixed
lineage state, keeping the dual-potential to become alveolar and bronchiolar cells
during passages. Consistently, BASC-A contained morphologically bronchiolar,
alveolar and mixed tumoroids (Figure 5.10b).

Next, we tested first generation TKI erlotinib, second generation TKI
afatinib, third generation TKIs osimertinib and rociletinib, pan-receptor tyrosine
kinase (RTK) inhibitor Dovitinib, HDAC6 inhibitor Ricolinostat and BCL-2 inhibitor
Venetoclax on AT2-a, BASC-A and BASC-B tumoroids. Overall, tumoroids had
lower IC50 values for third generation TKIs than the first and second generation
TKIs (Figure 5.11). Interestingly, it showed that AT2-A and BASC-A tumoroids
were significantly more sensitive to third generation TKI rociletinib than BASC-B
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tumoroids in in vitro 3D culture (adjusted p=0.02, and adjusted p=0.0036,
respectively, Figure 5.12). BASC-B tumoroids also had 2.5-fold higher IC50 to
osimertinib than AT2-A. Similar results were observed in EGFR TL-driven lung
cancer previously, which the peripheral tumors were relatively more sensitive to
HKI-272, an irreversible EGFR inhibitor, than the bronchial tumors
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.

No

significant difference of IC50 values was observed in these tumoroids to afatinib.
Expectedly, erlotinib did not manifest a potent therapeutic effect on these
tumoroids with T790M mutation. On the contrary, BASC-B were more responsive
to dovitinib than the AT2-A tumoroids. Venetoclax also harbored a lower IC50 in
BASC-B than BASC-A and AT-2 tumoroids. Since the alveolar and bronchiolar
tumoroids had the same mutations, these results suggested that different
epigenetic states affected the drug vulnerabilities to TKIs and other therapies.

Lastly, we aimed to detect potential therapies which could combine with and
improve the therapeutic effect of TKIs in the relatively insensitive tumors.
According to the GSEA results from Figure 5.9b comparing post-transplant
tumoroids with pre-transplant organoids which indicated that MYC, mTOR and
EZH2-target pathways were enriched during the in vivo transformation, we then
tested osimertinib combined with EZH2 inhibitor EPZ-6438/tazemetostat, BET
inhibitor JQ1 which was proved to suppress MYC function, or PI3K/AKT/mTOR
pathway inhibitor copanlisib on EGFR-mutant tumoroids and lung cancer lines 344346

. It showed that JQ1 and copanlisib combined with osimertinib led to significantly

more potent inhibitory effect than using these drugs alone in BASC-A tumoroids
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(Figure 5.13a). EPZ-6438 combined with osimertinib also induced a lower cellular
survival than EPZ-6438 alone, but not significantly lower than osimertinib alone. In
the previous studies, EZH2 inhibitor has been observed to reverse gefitinib
resistance in EGFR-wildtype lung cancer and synergize with HER2-targeted
breast cancer treatment, but also showed conflicting results of conferring
resistance to gefitinib in lung cancer347-349. It has been reported that irreversible
TKI synergized with mTOR inhibitor rapamycin in peripheral and bronchial EGFR
TL tumors 343. PI3K-AKT-mTOR inhibitor was also shown to sensitize lung cancer
cells to or overcome resistance to EGFR-TKIs 350-355. BET inhibition was reported
to delay the acquired resistance to anti-EGFR antibody in head and neck
squamous cell carcinoma, and synergize with anti-HER2 TKIs in lung cancer and
breast cancer as well

356-358

. Therefore, we verified these synergistic effects in

human cell lines PC9-GR4 and H1975, which both possess EGFR T790M
mutation. H1975 also had EGFR L858R mutation. The synergy matrix of
osimertinib combined with EPZ-6438 or copanlisib both displayed vigorous
synergist effect in PC9-GR4 and H1975 (Figure 5.13b). JQ1 also had synergy with
osimertinib in H1975 but not in PC9-GR4, suggesting that PC9-GR4 cell line
possibly harbors mutations antagonistic towards BET inhibition. Together, these
data shed light on promising therapeutic combination with third generation TKIs in
EGFR mutant lung cancers.
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a

b

Figure 5. 10 Bronchiolar and alveolar tumor tumoroids differ in lineage markers
and morphologies

(a) Relative mRNA expression of lineage genes in the indicated mouse 3D
tumoroids determined by RT-qPCR, n=3 or 4 technical replicates for each
genotype. (b) Representative bright field images of the indicated 3D tumoroids
propagated in the transwells.
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Figure 5. 11 Bronchiolar and alveolar tumor tumoroids have distinct IC50 to
therapies

Averaged IC50 of the indicated drugs calculated by the log(inhibitor) versus
response curves.
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Figure 5. 12 Bronchiolar and alveolar tumoroids respond to therapies
differentially
Dose responses to drugs osimertinib, rociletinib, afatinib, dovitinib, ricolinostat and
venetoclax in the indicated tumoroids.
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b

Figure 5. 13 Third generation TKI osimertinib synergizes with EZH2 inhibition,
BET inhibition and PI3K inhibition in lung cancer cells
(a) Percentage of survival of BASC-A tumoroids with the indicated treatments
compared to control. (b) Heatmap of Bliss synergy scores of osimertinib combined
with EPZ-6438, copanlisib and JQ1 in H1975 (left) 2D cultures with 3 technical
replicates used to produce an average matrix. Overall Bliss scores with 95%
confidence intervals were 1.36+/-3.82 for osimertinib+EPZ-6438, 3.36+/-3.56
osimertinib+copanlisib, and 7.82+/-2.49 osimertinib+JQ1. Most synergist area
Bliss scores were 13.20 for osimertinib+EPZ6438, 9.06 for osimertinib+copanlisib,
and 15.38 for osimertinib+JQ1. Heatmap of Bliss synergy scores of osimertinib
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combined with EPZ-6438, copanlisib and JQ1 in PC9-GR4 (right) 2D cultures with
3 technical replicates used to produce an average matrix. Overall Bliss scores with
95% confidence intervals were 11.6+/-2.6 for osimertinib+EPZ-6438, 9.18+/-1.79
osimertinib+copanlisib, and -9.1+/-1.43 osimertinib+JQ1.
Bliss

scores

were

16.08

for

osimertinib+EPZ6438,

osimertinib+copanlisib, and -0.43 for osimertinib+JQ1.
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Most synergist area
17.15

for

5.6

Summary and discussion
In our model system, most of the transplanted and autochthonous tumors

are alveolar. Even the bronchiolar BASCs formed mainly alveolar tumors. However,
in the similar EGFR TL mouse model, the bronchiolar tumors were not such rare
343

. The reason behind the difference might be because in our mouse model the

EGFR TL mutations were inserted into the collagen1a1 locus. The differentially
expressed genes of RNA-seq data indicated that genes related to various types of
collagen proteins were more frequently expressed in the alveolar cells than the
bronchiolar cells, possibly fostering a collagen-rich microenvironment friendly for
EGFR-mutant tumors to propagate. It may internally motivate the switch of
bronchiolar BASC organoids to alveolar tumors during in vivo transformation. Also,
interestingly, the tumor burdens of bronchiolar-derived tumors were larger than the
alveolar-derived tumors. It is known that both club cells and BASCs can give rise
to alveolar cells

230,359,360

. Besides, some research demonstrated that AT2 cells

might not be the major contributor of the regeneration of lung epithelium after
bleomycin injury, while CCSP-expressing cells may play a significant role in this
process

230,361-363

. It suggested that BASCs possessed a potent potential of

alveolar cell reconstruction.

We also discovered that basal and club cells were unable to yield
transplantable organoids when EGFR TL mutation was activated ex vivo. As lung
squamous cell carcinoma is proposed to be originated from basal cells, it implied
that EGFR-mutant squamous cell carcinomas might be derived from trans-
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differentiation of lung adenocarcinoma 334. However, the mechanism of why basal
and club cells could not develop in vivo tumors needs further study. It might be
because EGFR TL mutation drove mainly alveolar tumors, the cell type which
basal and club cells could not directly give rise to. Moreover, according to the
GSEA results, the basal and club cells did not significantly upregulate EGFR
signaling pathway when EGFR TL mutations were activated by Ad-Cre virus, which
might potentially prevent their further tumorigenesis in vivo.

The dose curve assays showed that bronchiolar and alveolar tumors
responded differentially to TKIs and other therapies. Especially, the third
generation TKI osimertinib and rociletinib targeting T790M gatekeeper mutation
were both more effective in the AT2-deived alveolar tumoroids than the BASCderived bronchiolar tumoroids. One possible theory is that bronchiolar and alveolar
cells possess different compositions of EGFR homo- and hetero-dimers, so that
they have different sensitivities to reversible, irreversible, and mutant-selective
TKIs

343

. According to our GSEA results, it is also possibly due to that EGFR

signaling pathway was more enriched in the bronchiolar tumoroids than the
alveolar ones. So, the bronchiolar cells might require higher dose of osimertinib
and rociletinib to achieve the same level of EGFR repression. However, its clinical
relevance needs to be further investigated.
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CHAPTER 6. SUMMARY AND FITURE DIRECTIONS

The projects above studied different aspects of epigenetic regulations in
non-small cell lung cancer. Chapter 3 demonstrated the dual effect of EZH2 by
using GEMMs which showed Ezh2 haplo- and full-insufficiency lead to divergent
phenotypes in KRAS+/Trp53-null lung ADC. Pharmacological inhibition of BET
proteins or H3K27 demethylases impeded tumor growth preferentially in PRC2deficient lung tumors in vitro and in vivo. Biochemical and transcriptional analysis
revealed PRC2 ablation-induced FOXP2 enrichment promotes lung tumor
stemness and migratory potency, partially phenocopying the effect of Ezh2
knockout in GEMMs. Moreover, FOXP2 could be attenuated by BET inhibitor JQ1.
This study promotes a profound understanding of the PRC2 complex in lung
cancer, which may be important for the use of EZH2 inhibitors in clinics. It also
provides a therapeutic combination of EZH2 inhibition with BET inhibition in lung
cancer patients. In the future, we will do ChIP-seq analysis on the cells with EZH2
deletion on H3K27me3 and FOXP2 to understand the roles of epigenetic
regulators and transcription factors in this scenario. Moreover, the altreations of
immune microenvironment in EZH2 deleted lung cancer need further
characterization. Preliminary results from our other studies in EZH2 inhibitor
combined with immunotherapies PD-1 inhibitor showed promising effects in lung
squamous cell carcinoma. However, immune system-related and tumor cellintrinsic mechanisms still need further investigation.
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Chapter 4 starts from an interesting discovery that PIK3CA-mutant
or amplified lung cancer cells were more sensitive to EZH2 inhibitor GSK126.
Then we characterized PIK3CA E545K, the most common mutation in lung cancer,
harbors a modest transformation capacity along with p53 loss in lung epithelial
cells,

and

can

drive

lung

adenocarcinoma

formation

autochthonously.

Furthermore, we showed that EZH2 inhibition synergized with PI3K inhibition in
human cancer cells in vitro and importantly in vivo. Given that PI3K inhibitor alone
did not have promising therapeutic effects in clinical trials, this study sheds light on
a potentially robust combinatorial therapy for patients with PIK3CA mutated or
amplified lung cancer. Mechanistically, we show that PIK3IP1, the negative
regulator of PIK3CA, may play a part in such synergy. However, further studies of
RNA-sequencing data on these cells will help us understand the pivotal
mechanisms in addition to PIK3IP1. Next, we plan to repeat copanlisib and
tazemetostat combination treatment in other xenografts and also Pic3ca/p53
mouse models, and if they show encouraging results, we can try to translate it into
clinical trials.
We also studied the cancer stem cells and their relativeness to treatments
in Chapter 5. Firstly, we describe a model of lung cancer with two clinically pivotal
EGFR mutations T790M and L858R, and a method to develop tumors of distinct
epigenetic states through three-dimensional (3D) organotypic cultures. We
discover that EGFR T790M/L858R mutations led to lung cancer with alveolar or
bronchiolar features, which can be originated from AT2 cells or BASCs, but not
basal cells or club cells of the trachea. These clones were able to retain their
162

epigenetic differences through passaging orthotopically in mice, and crucially that
they had distinct drug vulnerabilities, especially EGFR-TKIs, the most successful
targeted therapy strategy in lung cancer. This work paves road for exploring how
stem cell origins and epigenetic states can be used to stratify patients for precision
medicine decisions. In the future, we will query more clinical data and confirm
whether the alveolar or bronchiolar subtypes of lung cancer patients, an apparent
pathological or molecular difference basically neglected in clinics, do have
differential responses to EGFR-TKIs and other therapies. The cellular origins of
lung cancers with other mutations like PIK3CA can also be similarly investigated,
which will enhance the understanding of cancer biolgy.
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